1 CURRICULUM VITAE PERSONAL INFORMATION › files › 2020 › Lucchinetti CV.pdf · Clinical &...

1

CURRICULUM VITAE Claudia F. Lucchinetti, M.D.

PERSONAL INFORMATION

Place of birth: Chicago, Illinois Citizenship: United States

Home Address: 75 River Bluffs NW Rochester, Minnesota 55901 (507) 281-3983

Professional Address: Mayo Clinic Rochester 200 First Street S.W. Rochester, Minnesota 55905 (507) 284-2511

Additional Information: Spouse: Mathieu Wiepert

Children: Daniela Arianna (4/7/1999) Liana Michela (1/22/2002)

PRESENT ACADEMIC RANK AND POSITIONS

Chair – Department of Neurology, Mayo Clinic 2014-present Co-Chair integrated Medical Practice Neurosciences, Mayo Clinic 2016-present Enterprise Chair Dept of Neurology, Mayo Clinic 2016-present Consultant - Department of Neurology, Mayo Clinic; Rochester, MN 1999-Present Clinician Investigator, Department of Neurology Mayo Clinic 2013-Present Professor of Neurology Full Faculty Privileges, 2006-Present

Mayo Clinic, Rochester, MN

Clinical & Translational Science Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine and Science Mayo Clinic College of Medicine

Eugene and Marcia Applebaum Professor of Neuroscience 2019-present Board of Trustee Member, Mayo Clinic 2019-present Board of Governor; Member, Mayo Clinic 2019-present Council Member, National Institute of Neurological Disorders 2019-present Board of Directors, American Neurological Association 2019-present Mayo Clinic Proceedings Business Advisory Board 2020-present

EDUCATION Northwestern University - BA, Biology 1982 - 1986

Mayo Clinic in Rochester - Research Training, Summer Immunology Research Student - Mentor: Moses Rodriguez, M.D.

1984 - 1986

Rush Medical College - MD 1986 - 1990

Rush Presbyterian St. Luke's Medical Center - Internship 1990 - 1991

Mayo Graduate School of Medicine, Mayo Clinic College of Medicine - Resident, Neurology

1991 - 1994

Mayo Graduate School of Medicine, Mayo Clinic College of Medicine - Fellow, Neuroimmunology - Mentor: Moses Rodriguez, M.D.

1994 - 1995

2

Institute of Experimental Neurology, Universitat of Vienna - Fellow, Mayo Foundation Scholar - Mentor: Hans Lassmann

1995 - 1996

ADDITIONAL EDUCATION

Mayo Clinic Whitney MacMillan Physician Leadership Business Academy 2018

Rochester, Minnesota BOARD CERTIFICATIONS

National Board of Medical Examiners, Diplomat #394977 1991-present National Board of Neurology and Psychiatry 1996- present

LICENSURE

Illinois (Medical) 09/199 -1991

Minnesota 35544 (Medical) 09/1991-present

Florida ME 132537 (Medical) 05/2017-present

Arizona 54043 (Medical) 11/2017-present

HONORS/AWARDS

Freshman Honor Society; Northwestern University 1982 Sophomore Honor Society; Northwestern University 1983 Biology Honor Society; Northwestern University 1984-1986 Medical School Class Rank: Top 10% 1990 Clinical Honors: Pediatrics, Surgery, Neurology

Internal Medicine, Obstetrics and Gynecology 1988-1990 Upjohn Scientific Achievement Award 1990 Mayo Clinic Woltman Award for Clinical Excellence in Neurology 1995

Recipient of Frontiers in Neuroscience Lecture, Beyond the Decade of the Brain Plenary Session. (American Academy of Neurology) 2002 Active Member of American Neurological Association 2002 Fellow in American Academy of Neurology 2004

Recognized by Dept. of Internal Medicine as Outstanding Teacher 2014 Eugene and Marcia Applebaum Professor of Neuroscience 2015 2016 John Dystel Prize for Multiple Sclerosis Research (NMSS and the AAN Annual 2016

Meeting, Vancouver, Washington) Diversity Champion Award; Mayo Clinic 12/2018 Sheremata Lecture University of Miami 12/2019 Wartenburg Presidential Lecture: American Academy of Neurology 5/2019 Levy Lecture; Washington University, St Louis, Missouri 5/2020

PREVIOUS PROFESSIONAL POSITIONS AND APPOINTMENTS

Summer Immunology Research Student; Mayo Clinic 1984-1986

Instructor in Neurology - Mayo Clinic College of Medicine and Science 07/1994 - 06/1997

Senior Associate Consultant - Department of Neurology, Mayo Clinic, Rochester, Minnesota

1996 - 01/1999

Assistant Professor in Neurology - Mayo Clinic College of Medicine and Science

07/1997 - 06/2001

3

Associate Professor in Neurology - Mayo Clinic College of Medicine and Science

07/2001 - 10/2006

Associate Director - General Clinical Research Center, Mayo Clinic, Rochester, Minnesota

2003 - 2010

Master's Faculty Privileges in Clinical Research - Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine and Science

10/2003 - 06/2007

Master's Faculty Privileges in Clinical & Translational Sci. - Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine and Science

06/2007 - 09/2007

Division Chair – Division of Multiple Sclerosis and Autoimmune Neurology, Department of Neurology, Mayo Clinic, Rochester, Minnesota

2005 - 20014

Program Director: Multiple Sclerosis Fellowship

2001-2014

Associate Director-Center of MS and Demyelinating Disorder Chair; Research Personnel Subcommittee

2009-2014

2010-2014

PROFESSIONAL & COMMUNITY MEMBERSHIPS, SOCIETIES AND SERVICES

Professional Memberships & Services

Institute for Clinical Systems Integration Technology Assessment Committee

01/1997

Intravenous Immune Gamma Globulin (IVIG) for Treatment of Neurological Conditions Workgroup

01/1997

Minnesota Medical Association

Zumbro Valley Medical Society

Association of University Professors of Neurology

National Multiple Sclerosis Society Reviewer

International Task Force on Clinicopathologic Correlate of the MS Lesion

01/1999

Medical Advisory Board

American College of Physicians Neurology Section

01/1998 - 01/2000

Medical Knowledge Self-Assessment Program 01/1998 - 01/2000

American Academy of Neurology 01/2004

4

Central Society for Neurological Research 01/2002 - 2008

American Neurological Association Membership Advisory Committee

2007 - 2009

Basic Science Subcommittee Member

2007 - 2009

American Academy of Neurology Member of Science Committee

2015 – 2017

Sigma Xi, The Scientific Research Society 01/2004 - Present

Director, American Neurological Association (ANA) Board of Directors

08/2018 - present

National Institute of Neurological Disorders and Stroke Council. (NINDS)

08/012019 -present

Mayo Clinic Proceedings Business Advisory Board

2020-present

Study Sections

National Institutes of Health

Clinical Neuroimmunology and Brain Tumors Study Section Study Section Reviewer 2009 - Present

Standing Member 2010 - 2016

Chair 07/2012 - 06/2014

JOURNAL REVIEW AND EDITORIAL ACTIVITIES

Annals of Neurology *External Reviewer

Archives of Neurology *External Reviewer

Brain *External Reviewer

Brain Pathology *External Reviewer * Guest Editor, NMO Symposium 2014

Clinical Immunology *External Reviewer

International Multiple Sclerosis Journal *External Reviewer

Journal of Neurology *External Reviewer

Journal of Neuroimmunology

*External Reviewer Lancet

*External Reviewer

5

Multiple Sclerosis *External Reviewer

Nature *External Reviewer

Neurology *External Reviewer

New England Journal of Medicine * External Reviewer

EDUCATIONAL ACTIVITIES

Curriculum/Course Development and Coordination

Neuroscience Course 1994 Mayo Medical School

Physician Assistant Program (Seminar on Demyelinating Diseases) 1996

Mayo School of Health Related Sciences

Neurobiology of Human Disease Mayo Graduate School

1997, 1999

Oligodendrocytes and MS Mayo Graduate School

1998, 1999

Pathobiology of Disease; Multiple Sclerosis Mayo Graduate School

1999, 2000

Multiple Sclerosis Neuro-ophthalmology Residency Lecture Series Mayo Clinic College of Medicine

2000

Multiple Sclerosis Neurology Residency Lecture Series

1999, 2001, 2005

Neurology Advisor Program Mayo Clinic College of Medicine

2000-present

American College of Physicians: Preparation of Medical Knowledge Self Assessment Program, Neurology Section

1998-2000

CPC Coordinator Department of Neurology

2000-2002

Progress in Arresting MS: Unanswered Questions MS Advances and Evidence-Based Management Scottsdale, AZ, Mayo Clinic, College of Medicine Mayo School of CME

2/2003

Approach to Acute Leukoencephalopathies Faculty and Course Director American Academy of Neurology

2000-2004

6

Multiple Sclerosis Pathology Faculty American Academy of Neurology

2001, 2004, 2010, 2011

Multiple Sclerosis Update Faculty and Course Director American Academy of Neurology

2005-2009

Examiner for Mock Oral Boards, OSCE examinations Mayo Clinic College of Medicine

Multiple Sclerosis Therapy Update: What’s on the Horizon? 3/2005-present MS Update and Practical Management Strategies every other year Mayo School of CME, Scottsdale, AZ

Neuromyelitis Optica; Pathology and Pathogenesis 2009-2017 Faculty, American Academy of Neurology

Teaching

Neuroscience Course Mayo Medical School Rochester, Minnesota

02/1994 - 03/1994

Demyelinating Diseases Physician Assistant Program, Mayo School of Health Related Sciences Rochester, Minnesota

06/1996

Neurobiology of Human Disease Course Mayo Graduate School Rochester, Minnesota

03/1997

Graduate Neuroscience Course Mayo Graduate School Rochester, Minnesota

03/1998 - 04/1998

Pathobiology of Disease Mayo Graduate School Rochester, Minnesota

01/1999 - 01/2000

Examiner for mock Oral Boards, OSCE examinations Mayo Graduate School of Medicine Rochester, Minnesota

01/1999 - Present

Graduate Neuroscience Course Mayo Graduate School Rochester, Minnesota

02/1999

Neurology Residency Lecture Series Mayo Graduate School of Medicine Rochester, Minnesota

08/1999

7

Neurobiology of Human Disease Course Mayo Graduate School Rochester, Minnesota

10/1999

Neurology Advisor Program Mayo Graduate School of Medicine Rochester, Minnesota

01/2000 - Present

Ophthalmology Residency Lecture Series Mayo Graduate School of Medicine Rochester, Minnesota

01/2000

Neurology Residency Lecture Series Mayo Graduate School of Medicine Rochester, Minnesota

08/2001

Progress in Arresting MS: Unanswered Questions Mayo School of CME MS Advances and Evidence-Based Management Scottsdale, Arizona

02/2003

Pathogenic Heterogeneity in Multiple Sclerosis Multiple Sclerosis: Advances and Evidence-Based Management: (CME Course) Scottsdale, Arizona

02/2003

Multiple Sclerosis Update Faculty and Course Director American Academy of Neurology

2005

Multiple Sclerosis Therapy Update; What’s in the Horizon 2005 MS Update and Practical Management Strategies Mayo School of CME Scottsdale, Arizona

03/2005

Clinical Implications of MS Pathology

2005 MS: Update and Practical Management Strategies. CME Course Scottsdale, Arizona

03/2005

MS Subtypes Practicum in Neurology Chicago, Illinois

04/2006

Understanding the Pathologic Basis of Progression in MS CME Conference on Progressive MS Kiawah, South Carolina

07/2006

Taking a microscopic look at MS Neurological Update 2007 Miami, Florida

01/2007

The spectrum of inflammatory CNS demyelinating disorders Neurological Update 2007 Miami, Florida

01/2007

8

Differential Diagnosis of Inflammatory Demyelinating Disease: The Multiple Sclerosis Mimickers Mayo Neuro CME Course Chicago, Illinois

07/2009

MS Mimickers Mayo Neuro CME Course Chicago, Illinois

07/2012

The Cortex in MS Mayo MS CME Course Phoenix, Arizona

03/2013

MENTORSHIP – Summer Students/Graduate Students/Postdoctoral Fellows/Medical

Students/Visiting Scientists

Mark B. Keegan, M.D., Postdoctoral Fellow 1999-2001

Istvan Pirko, M.D., Postdoctoral Fellow 2001-2003

Ayse Altintas, M.D., Postdoctoral Fellow 2002-2003

Sean Pittock, M.D., Postdoctoral Fellow 2003-2004

Yazmin Morales,MBBS, MD, Clinical Research Training Program Master’s Thesis

2003-2005

Association of T cell Subsets and HLA Polymorphisms with Tissue Injury and Repair of MS Lesions. Successfully defended, and published 5/2005. Yazmin Morales was awarded the highest honor from the Prtizker University of Chicago School of Medicine given to a non-PhD student for her research project conducted in Dr. Lucchinetti’s laboratory and under her mentorship.

Imke Metz, M.D. Postdoctoral Fellow University of Goettingen 2005

Nathan Staff, M.D., Neurology Resident 2005

Ralitza Gavrilova, M.D., Postdoctoral Fellow 2004-2005

Nathan Young, D.O., Neurology Senior Research Project 2005-2006

Orhun Kantarci, M.D., Postdoctoral Fellow 2005-2006

Setty Magaña, Clinical Research Training Program Master’s Thesis 2005-2007

Shanu Roemer, M.D., Post-doctoral Fellow 2005-2007

Nilufer Kale, M.D., Postdoctoral Fellow 2006-2010

Brendan Kelley, M.D., Postdoctoral Fellow 2007-2008

Nuhad Abou Zeid, M.D. Postdoctoral Clinical and Research Fellow 2007-2009

9

Setty Magaña, CTSA PhD 2007-2011 PhD Thesis Advisor and Committee Chair: Pathogenic Reversibility and Therapeutic Relevance In Humorally-Mediated Central Nervous System Inflammatory Diseases

Josa Frischer, M.D., Research Trainee, University of Vienna 2008

Wei Hu, M.D., Ph.D., Postdoctoral Clinical and Research Fellow 2008-2009 *Recipient of Harvard Partner’s Research Scholarship

Caitlin Harper, Summer Student, St. Olaf College 2009

Reem Bunyan, M.D., Post-doctoral Clinical and Research Fellow 2009-2011 Awarded Master’s thesis (CTSA)

Bogdan Popescu, M.D., Ph.D., Postdoctoral Fellow 2009-2011

Chiara Costanzi, M.D., Postdoctoral Fellow, University of Brescia 2009-2012

Jennifer Ayers-Ringler, Pre-doctoral Fellow 2010-2013 Mayo Graduate School PhD Thesis Advisor and Committee Chair

Yong Guo, M.D.; PhD; Postdoctoral Research Fellow 2011-present

Dawn Eggert; PhD; Research associate 2011-2012

Jan-Mendelt Tillema; MD; Clinical Fellow/Junior staff 2011-present

Megan Rahmlow; MD; Clinical Fellow 2011-2012

Oliver Tobin, MD, Clinical Fellow/Junior staff 2013-present

Maggie Caulfield, PhD, Postdoctoral Fellow 2014-2017

Josa Frischer, MD, PhD, Postdoctoral Fellow 2014-2015 *Recipient of prestigious fellowship from Vienna to train in Dr. Lucchinetti’s lab

Sunjae Hwang, M.D., Postdoctoral Fellow 2015-2016

Michael Dayan, Ph.D., Postdoctoral Fellow 2016-2017

Parijat Kabiraj, Ph.D., Postdoctoral Fellow 2016- 2019

Oleksandr Gakh, Ph.D., Postdoctoral Fellow 2107-present

Monica Giraldo Chica, Ph.D. Postdoctoral Fellow 2107-2018 Jordan Wilkins, Post-doctoral fellow 2018-present

10

Honors and Awards for Education

Outstanding Teacher Award - Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota

2014

INSTITUTIONAL/DEPARTMENTAL ADMINISTRATIVE RESPONSIBILITIES, COMMITTEE MEMBERSHIPS, AND OTHER ACTIVITIES

Institution Mayo Clinic Board of Governors, Member 02/2019 - present Mayo Clinic Board of Trustees, Member 02/2019 - present Center of MS and Demyelinating Disorders, Associate Director 2009 – 2014 Personnel Committee Member 01/2009 – 2014 Research Personnel SubCommittee; Chair 01/2010 - 2014 Research Committee 01/2010 - 2018 Midwest Financial Group 03/2016 Member, Team Science Task Force 2014 Research Metrics Task Force; Vice Chair 2012-2013 Research Review Group 2013-2014 General Clinical Research Center Advisory Committee Member 01/2002 - 12/2006 Associate Director, Clinical Research Unit 01/2006 – 12/2010 Member 01/2000 – 2010 Coordinator 01/2000 – 12/2002 Center for Multiple Sclerosis and Demyelinating Diseases Assistant Director 2009 - 2014 Division of MS and Autoimmune Neurology, Chair 2005 - 2014

Department Neurology Executive Committee 2006 - Present Resident Assessment Committee, Member 01/1998 - Present Resident Education Committee, Member 01/1998 - Present

Section of Multiple Sclerosis Section Chair, Rochester, Minnesota 2003 - 2009 Practice Enhancement Project

Outpatient Practice Team, Member 09/1996 - 04/1997 Resident Recruitment Committee, Chair 01/1998 - 01/2002

Resident Selection Committee, Member 01/1992 - 01/1994

NON-INSTITUTIONAL/DEPARTMENTAL, ADMINISTRATIVE RESPONSIBILITIES, COMMITTEE MEMBERSHIPS, AND OTHER ACTIVITIES

Council for National Institute of Neurological Disorders, NIH Member

2019 - present

American Neurological Association Board of Directors Director

2019 present

Professional Development Committee, American Neurological Association

2015-2018

11

American Association of Neurology, Science Committee Member 2015 – 2017

Charter Member, NIH Study Section, CNBT Chair

2010-2016 7/1/2012-6/30/2014

Basic Science Subcommittee; American Academy of Neurology

2007-2009

Membership Selection Committee; American Neurological Association

2005-2008

NIH Study Section: Clinical Neuroimmunology & Brain Tumor (CNBT) Ad Hoc Member

6/2009,10/2009,2010

International Task Force on Clinicopathologic Correlate of the MS Lesion Multiple Sclerosis Society (USA)

1999

EXTRAMURAL ACTIVITIES

Intravenous Immune Gamma Globulin (IVIG) for Treatment of Neurological 1997 Conditions. Preparation of Report for Technology Assessment Committee with Institute for Clinical Systems Integration.

INVITED PRESENTATIONS AND VISITING PROFESSORSHIPS (not complete)

Invited Presentations

The Clinicopathologic Spectrum of Fulminant Multiple Sclerosis University of Goettingen Goettingen, Germany

01/1996

Patterns of Demyelination and Oligodendrocyte Pathology in Early Multiple Sclerosis University of Vienna Vienna, Austria

01/1996

The Epidemiology and Course of MS Multiple Sclerosis Symposium Boston, Massachusetts

10/1997

Patterns of Oligodendrocyte Immunopathology in Early MS Symposium on Multiple Sclerosis Pathology Vienna, Austria

11/1997

Patterns of Multiple Sclerosis Immunopathology American Society of Neurochemistry Denver, Colorado

03/1998

Demyelination in Multiple Sclerosis and Biologic Markers of Disease Activity in MS. Spanish Multiple Sclerosis Society - International University Mendez Pelayo Santander, Spain

06/1998

12

Heterogeneity of Multiple Sclerosis Lesions: Implications for the Pathogenesis and Treatment of MS. American Society of Neurochemistry Chicago, Illinois

03/2000

The Pathobiology of Multiple Sclerosis

United Leukodystrophy Foundation Annual Meeting Chicago, Illinois

06/2000

Heterogeneity in MS Pathology Multiple Sclerosis Symposium: The Neurobiology and Immunobiology of Multiple Sclerosis Boston, Massachusetts

10/2000

Structural Heterogeneity in MS Lesions International Symposium on Multiple Sclerosis: Pathology and Pathogenesis Berlin, Germany

11/2000

Immunopathogenesis of MS

National Multiple Sclerosis Society Symposium Boston, Massachusetts

12/2000

The Pathology of MS: Evidence for Subtypes. Consortium of MS Centers Annual Meeting Ft. Worth, Texas

06/2001

Pathology of MS NIH Workshop: Chemokines in MS Washington, District of Columbia

07/2001

Pathophysiology of Devic's Disease Transverse Myelitis Association Annual Meeting Baltimore, Maryland

07/2001

The Heterogeneity of the MS Lesion. 17th Congress of the European Committee for Treatment and Research in MS (ECTRIMS) Dublin, Ireland

09/2001

Clinicopathological Correlates of the MS Lesion National Multiple Sclerosis Society Symposium Houston, Texas

10/2001

Unraveling the Mystery of the MS Lesion National MS Society Leadership Conference New Orleans, Louisiana

11/2001

Unraveling the Mystery of the MS Lesion. Pathogenic Clues and Therapeutic Hints. American Academy of Neurology Frontiers in Clinical Neuroscience: Beyond the Decade of the Brain. Denver, Colorado

04/2002

13

Pathology of MS Subtypes Consortium of MS Centers Annual Meeting Chicago, Illinois

06/2002

The Pathology of Primary Progressive MS Round Table Discussion on Primary Progressive MS Houston, Texas

11/2002

Pathogenic Heterogeneity in Multiple Sclerosis Multiple Sclerosis: Advances and Evidence-based Management: CME Course Scottsdale, Arizona

02/2003

Merging of Minds and Matter 19th Congress of the European Committee for Treatment and Research in MS (ECTRIMS) Milan, Italy

09/2003

The Pathology and Immunopathology of Acute MS Lesions MAGNIMS Clinically Isolated Syndrome Workshop London, United Kingdom

09/2003

MRI Correlates of Heterogeneous Multiple Sclerosis Pathology American Neurological Association San Francisco, California

10/2003

The Histopathological Correlates of Ring-Enhancement in Multiple Sclerosis Lesions American Neurological Association San Francisco, California

10/2003

Heterogeneous MS Pathology; Implications for Remyelination Gordon Research Conference on Myelin Barga, Italy

05/2004

Insights from the MS Lesion Project: Clinical and Paraclinical Correlates of MS Lesion Heterogeneity Neuroscience Research Symposium Toronto, Ontario, Canada

09/2004

Unraveling the Mystery of MS Invited Lecture NMSS North California Chapter Annual Research Symposium Sacramento, California

11/2004

Clinical Implications of MS Pathology 2005 MS Update and Practical Management Strategies. CME Course Scottsdale, Arizona

03/2005

The Pathology of MS

J.L. Trotter Symposium St. Louis, Missouri

08/2005

14

Multiple Sclerosis Pathogenesis and Experimental Models Marine Biology Laboratory graduate course series Woodshole, Massachusetts

08/2005

Multiple Sclerosis. Clinical Implications of the MS Lesion Key Note Speaker Italian Society of Neuroimmunology; Padova, Italy

10/2005

The MS Lesion Project Annual National MS Society Meeting Reno, Nevada

11/2005

MS Subtypes Practicum in Neurology Chicago, Illinois

04/2006

Multiple Sclerosis Update Aegean Meeting on Neurologic Therapeutics Crete, Greece

05/2006

MS Immunopathology Alliance MS Conference Seattle, Washington

05/2006

Understanding the Pathologic Basis of Progression in MS CME Conference on Progressive MS Kiawah, South Carolina

07/2006

Pathologic Evidence for Immune Effector Heterogeneity in MS Second International Rare Neuroimmunologic Disorders Symposium Baltimore, Maryland

07/2006

MS Pathogenesis: From the microscope to the bedside. Turkish Neurological Association Istanbul, Turkey

11/2006

Taking a Microscopic Look At MS and The Spectrum of Inflammatory CNS Demyelinating Disorders. Neurological Update 2007 Miami, Florida

01/2007

Multiple Sclerosis Update

Annual Neurological Association Meeting Iowa City, Iowa

02/2007

Heterogeneity in MS MS Frontiers London, United Kingdom

06/2007

15

Multiple Sclerosis Update Course on Pathogenesis of Neuroimmunology Woodshole, Massachusetts

08/2007

Homogeneity vs. Heterogeneity in MS: Stage-dependent or patient-dependent ECTRIMS

Prague, Czech Republic

10/2007

Multiple Sclerosis and Neuromyelitis Optica: From Pathology to Pathogenesis National MS Society (Wisconsin Chapter) Madison, Wisconsin

10/2007

B Cells in Autoimmunity and MS CALLOSUM Santa Monica, California

01/2008

The Spectrum of CNS Inflammatory Demyelinating Diseases: From Pathology to Pathogenesis American Association of Neuropathologists San Diego, California

04/2008

Update on the MS Lesion Project: from Pathology to Pathogenesis Consortium of Multiple Sclerosis Centers (CMSC) Denver, Colorado

05/2008

Update on the Multiple Sclerosis Lesion Project: From Pathology to Pathogenesis Consortium on Multiple Sclerosis Centers Annual Meeting Denver, Colorado

05/2008

Update on NMO Mini-MS Symposium Minneapolis, Minnesota

05/2008

Pathology and Pathogenesis of the MS Lesion Denver CME Conference Denver, Colorado

09/2008

MS Pathology

Tykeson Fellowship Conference on MS Chicago, Illinois

11/2008

Update on NMO Wayne State University Detroit, Michigan

11/2008

Evolution of Pathogenic Concepts: From White Matter to Cortex Keystone MS Symposium Santa Fe, New Mexico

01/2009

16

Evolution of MS Pathogenic Concepts American Society of Neurochemistry Charleston, South Carolina

03/2009

Neuromyelitis Optica: Scientific and Clinical Update American Academy of Neurology Seattle, Washington

04/2009

Differential Diagnosis of Inflammatory Demyelinating Disease: The Multiple Sclerosis Mimickers Mayo Neuro CME Course Chicago, Illinois

07/2009

A New Way to Think about MS Pathology CME Conference: Update on MS and Parkinson’s Disease Kiawah, South Carolina

09/2009

The Pathology of Relapses and Progression in MS ECTRIMS Dusseldorf, Germany

09/2009

NMO Roundtable Conference Los Angeles, California

11/2009

CMSC Consensus Meeting CMSC Consensus Meeting Short Hills, New Jersey

03/2010

Neuromyelitis Optica: Pathology and Pathogenesis American Academy of Neurology Toronto, Ontario, Canada

04/2010

Neuromyelitis Optica American Neurological Association San Francisco, California

09/2010

CNS Autoimmunity Targeting Water Channels American Neurological Association San Francisco, California

09/2010

CNS Autoimmunity Targeting Water Channels International Society for Neuroimmunology Barcelona, Spain

10/2010

NMO Roundtable Los Angeles, California

11/2010

Emerging Trends in MS: Pathology and Pathogenesis NYU CME Course New York, New York

11/2010

17

What Pathology Tells Us about MS Disease Course and Therapy CMSC 25th Annual Meeting Montreal, Quebec, Canada

06/2011

Pathological Heterogeneity in MS: YES Top Seminars in Multiple Sclerosis Milan, Italy

06/2011

Antibody Mediated Dysfunction American Society for Neuroscience Annual Meeting Washington, District of Columbia

11/2011

NMO Roundtable NMO Roundtable Los Angeles, California

11/2011

The role of MRI measures in Gray Matter Pathology and Cortical Lesions in Clinical Trial Design and Clinical Practice Biogen Idec National Advisory Committee Miami, Florida

02/2012

NMO Update American Academy of Neurology New Orleans, Louisiana

04/2012

Update of the MS Lesion Project 17th Congress Association of Italian Neuroimmunology and Neuropathology Verona, Italy

05/2012

Cortical Pathology in MS: Implications for Disease Pathogenesis MS Symposium, University of Verona Verona, Italy

05/2012

Gray Matter in MS CMSC 26th Annual Meeting San Diego, California

06/2012

MS Mimickers CME Course Chicago, Illinois

07/2012

Inflammatory Cortical MS Pathology ECTRIMS Lyons, France

10/2012

Evidence for Diseases Heterogeneity in MS: Update on Controversy Symposium on MS: Insights from the Microscope to the Bedside Porto, Portugal

01/2013

NMO Update American Academy of Neurology San Diego, California

03/2013

18

CMSC 26th Annual Meeting Mayo MS CME Course Phoenix, Arizona

03/2013

Inflammatory Cortical Pathology in Early MS: Implications for Disease Pathogenesis Neuroinflammation Research Symposium Toronto, ON, Canada

04/2013

Pathogenesis of MS Lesions Northern Lights MS Symposium Turka, Finland

05/2013

Cortical Pathology in MS: The Gray Matter Matters NMSS Charcot Lecture Washington, DC

06/2013

Taking a Microscopic Look at Multiple Sclerosis: Clinical and Pathogenic Implications Simposio Internacional de Neurología de Santiago (SINS) Santiago, Chile

07/2013

Neuromyelitis Optica: A CNS Autoimmune Channelopathy Simposio Internacional de Neurología de Santiago (SINS) Santiago, Chile

07/2013

Multiple Sclerosis Mimickers: A Case-Based Approach Simposio Internacional de Neurología de Santiago (SINS) Santiago, Chile

07/2013

Taking a Microscopic Look at MS: Pathogenic and Clinical Implications Academia Puertorriqueña de Neurología (APN) Dorado, Puerto Rico

08/2013

Gray Matter Pathology in MS Academia Puertorriqueña de Neurología (APN) Dorado, Puerto Rico

08/2013

Heterogeneity in MS

German Society for Neuropathology and Neuroanatomy (DGNN) Göttingen, Germany

09/2013

Progressive MS Pathology: Role of Cortical Lesions, Deep Gray Structures, and Spinal Cord American Neurological Association New Orleans, Louisiana

10/2013

NMO Update American Academy of Neurology Philadelphia, Pennsylvania

05/2014

19

New Insights and Future Directions in MS Pathology CMSC 28th Annual Meeting Dallas, Texas

05/2014

Update on the MS Lesion Project

Neurorehabilitation Summit: Regeneration, Recovery & Reintegration Rochester, Minnesota

05/2014

Mechanism of the Progression of MS Novartis MS Future Forum 2014 Montreal, Canada

10/24/2014

Center for Brian Immunology and Glia-Department of Neuroscience, School of Medicine, University of Virginia, Charlottesville, VA Title of Talk: “Neuromyelitis Optica: An Autoimmune Systemic Channelopathy”

12/10-11, 2014

Killam Research Seminar, McGill University, Montreal, Quebec Title of Talk: “Neuromyelitis Optica: A Systemic Disease Targeting Water Channels Objectives”

2/3-4, 2015

Longwood Neuro Grand Rounds, Beth Israel Deaconess Medical Center, Boston, MA Title of Talk: NMO: Paradigm of an Autoimmune Channelopathy

2/24-25, 2015

9th World Congress on Controversies in Neurology, Budapest, Hungary Title of Talks: “In spite of Heterogeneity, MS Progression Reflects Shared Critical Mechanisms” and “NMO and MS: Same or Different Pathologies: Pathological Differences”

3/26-28/2015

AAN Meeting, Washington, DC Participated in “Leadership for Women”

4/18-25, 2015

Annual Meeting of the Consortium of the Multiple Sclerosis Centers (CMSC), Indianapolis, IN Title of Talk:” Neuromyelitis Optica and Other CNS Demyelinating Diseases, Pathological Features of CNS Demyelinating Disease: Can pathology lead to specific diagnosis?”

5/27-30, 2015

Neurology in Clinical Practice, Chicago, IL Title: Multiple Sclerosis Mimickers

7/16-18, 2015

Istanbul MS Days 2015 Istanbul, Turkey Title: Pathological hallmarks of the MS and other idiopathic inflammatory demyelinating diseases

11/13-15, 2015

20

2016 Breakthroughs in Neurology Conference Orlando, Florida Title: The Spectrum of MS and Its Mimickers

1/15–18, 2016

ACTRIMS Forum 2016 New Orleans, LA Title: Lymphoid follicles, cortical inflammation and clinical features

2/18-20, 2016

Annual Meeting of The American Association of Immunologists, IMMUNOLOGY 2016. (Major Symposium on Neuroimmunology). Seattle, WA Title of Talk: NFkB signaling drives pro-granulocytic astroglial responses to the neuromyelitis optica IgG: Pathogenic and Therapeutic Implications.

5/13–17, 2016

Regional MS Summit Seattle, Washington Title: The spectrum and treatment of CNS Inflammatory Disorders: From the Microscope to the Bedside

6/11/2016

Novartis Grand Rounds Newark, NJ Clinical-Radiographic Correlates of MS Pathology

11/14-15, 2016

University of Pennsylvania Grand Rounds (invited) Philadelphia, PA Title: Neuromyelitis Optica: A Systemic Aqauporin-4 Autoimmune Channelopathy

12/14/2016

Mayo Clinic Multiple Sclerosis and Autoimmune Neurology Course Phoenix, Arizona Title: MS Progression: An Immunopathological Perspective

2/10/2017

Gordon Research Conferences – Neuroimmune Communication in Health & Disease Ventura, CA

Title: Pathogenic and Clinical Implications of MS Immunopathological Heterogeneity

1/15-20/17

Biogen XRF Study Cambridge, MA Title: Metals in MS Pathology: XRF maps and qualitative histopathology in chronic and acute MS

1/31 – 2/1/ 17

Annual Meeting of the Consortium of Multiple Sclerosis Centers New Orleans, LA Lecture given: May 25, 2017

Title: Neuromyelitis Optica: Pathogenic Insights on an Autoimmune AQP4 Channelopathy

5/24-27/17

21

7th Joint Ectrims – Actrims Meeting Paris, France Title: Evolution of MS Plaques (10/26)

10/25 – 27/ 2017

2018 Alpers Lecture Jefferson University Philadelphia, Pa Titles (2 presentations)

1. Evolution of the MS Plaque: Pathogenic and Treatment Implications (Thursday)

2. Neuromyelitis Optica: A Systemic Autoimmune Channelopathy (Friday)

5/24-25/2018

2018 Annual Meeting of the Consortium of Multiple Sclerosis Centers Nashville, TN John Whitaker Memorial Lecture Title: New Insights into MS Pathology Using Synchrotron X-ray Fluorescence Imaging (SXRF)

05/31-06/01/18

Mayo Clinic Multiple Sclerosis and Autoimmune Neurology 2019 Phoenix, AZ Title: Multiple Sclerosis Pathology

2/8-9, 2019

Neurology in Clinical Practice 2019 Honolulu, HA Title: From the Microscope to Bedside: Insights on the Spectrum of CNS Inflammatory Demyelinating Diseases

7/19/19

American Academy of Neurology 2019 Sunday, May 5, 2019 Robert Wartenberg Lecture – Progress in Understanding Progressive MS: From the Microscope to the Bedside Philadelphia PA

05/05/2019

Visiting Professorships (not complete)

The Clinicopathologic Spectrum of Fulminant Multiple Sclerosis University of Gottingen Gottingen, Germany

01/1996

Patterns of Demyelination and Oligodendrocyte Pathology in Early Multiple Sclerosis University of Vienna Vienna, Austria

01/1996

The Immunopathogenetic Spectrum of MS Grand Rounds, Cleveland Clinic Cleveland, Ohio

04/1998

Heterogeneity in Multiple Sclerosis Pathology Grand Rounds, Rush Medical College Chicago, Illinois

04/2000

22

Update on the Immunopathology of MS Oregon Health Science University Portland, Oregon

11/2001

Pathogenic Spectrum of MS Grand Rounds Pathology Department, Oregon Health Science University

11/2002

Neurology Grand Rounds John Hopkins

03/2003

Neurology Grand Rounds Case Western

04/2003

Invited Visiting Professor Grand Rounds: Neurology Columbia University Neurology Grand Rounds New York, New York

05/2003

Department of Neurology, UC Davis Sacramento, California

10/2003

Department of Neurology, University of Wisconsin Madison, Wisconsin

03/2004

McEwan Invited Professor Department of Neurology, Toronto Western Hospital Toronto, Ontario, Canada

09/2004

Insights from the MS Lesion Project: Clinical and Paraclinical Correlates of MS Lesion Heterogeneity Neuroscience Research Symposium; St. Michael’s Hospital Toronto, Ontario, Canada

09/2004

Western Hospital Toronto, Ontario, Canada

09/2004

Department of Neurology, Washington University Medical School St. Louis, Missouri

08/2005

Multiple Sclerosis Pathogenesis and Experimental Models Marine Biology Laboratory Graduate Course Series Woods Hole Oceanographic Institution Woodshole, Massachusetts

08/2005

Department of Neurology: Wayne State University Detroit, Michigan

09/2005

Department of Neurology; University of New Mexico Health Sciences Center Albuquerque, New Mexico

11/2005

23

Wayne State University Detroit, Michigan

12/2005

Department of Neurology, University of Cincinnati Cincinnati, Ohio

05/2006

Department of Neurology; University of Minnesota Medical School Minneapolis, Minnesota

05/2006

Department of Neurology, Harvard University Boston, Massachusetts

06/2006

Department of Neurology, Cleveland Clinic Cleveland, Ohio

01/2007

Department of Neurology, Northwestern University Medical Center Chicago, Illinois

05/2007

Department of Neurology, Halifax University Halifax, Canada

02/2009

Department of Neurology, University of Connecticut Medical School Hartford, Connecticut

02/2009

Department of Neurology, University of Massachusetts Boston, Massachusetts

06/2009

Department of Neurology, University of Michigan Ann Arbor, Michigan

09/2010

Department of Neurology, University of Connecticut Medical School Hartford, Connecticut

01/2011

Department of Neurology, University of Pennsylvania Philadelphia, Pennsylvania

01/2011

Department of Neurology, University of Vermont Burlington, Vermont

04/2011

Department of Neurology, Yale University New Haven, Connecticut

09/2011

Department of Neurology, Mount Sinai School of Medicine New York, New York

11/2011

Department of Neurology, North Shore Hospital Evanston, Illinois

12/2011

Department of Neurology, Rush University Chicago, Illinois

02/2012

24

Department of Neurology, Emory University Atlanta, Georgia

03/2012

Department of Neurology, UT Southwestern Dallas, Texas

07/2012

National Institutes of Health Bethesda, Maryland

06/2013

Wayne State University Detroit, Michigan

04/2014

University of Maryland, Grand Rounds Baltimore, Maryland

05/2014

Stanford University, Department of Neurology Grand Rounds San Francisco, CA

9/2014

University of Virginia Charlottesville, Virginia

Longwood Neurology Grand Rounds Harvard Medical School Boston, MA

12/2014

2/2015

Iowa Grand Rounds Iowa City, Iowa Title of Talk: New Insights about Neuromyelitis Optica: A Systemic Autoimmune Channelopathy

8/2015

Grand Rounds Department of Neurology SUNY Downstate Medical Center Brooklyn, New York Title of talk: Neuromyelitis Optica: Update on a Systemic AQP4 Autoimmune Channelopathy

4/8/2016

Grand Rounds University of Washington Seattle, Washington Title: Neuromyelitis Optica: A Systemic Autoimmune Channelopathy

6/9/2016

2017 Spectrum Health Neurosciences Symposium Medical Education Partners Title: The Spectrum, Mimics and Treatment of MS: From the Microscope to the Bedside

Wellesley Neuroscience Speaker Boston, MA Title: Astrocytes and Aquaporins: Relevance to Neurologic Disease

5/12/2017

11/29-30/18

25

Grand Rounds at Cedars Sinai Los Angeles, CA Title: Neuromyelitis Optica: A Systemic Autoimmune Channelopathy

4/18-19, 2019

William Sheremata Lecture September, 2019 University of Miami Title: Progress in Progressive MS: From the Microscope to the Bedside

12/5-6, 2019

Grand Rounds at Northwestern University Chicago IL Title: Progress in Progressive MS: From the Microscope to the Bedside

01/16/2020

Grand Rounds- Kenneth Johnson Memorial Lecture Baltimore, MD Title: Progress in Progressive MS: From the Microscope to the bench

03/04/2020

2020 Levy Lecture at Washington University for the Department of Neurology Saint Louis, MO Title: TBD

06/12/2020

PRESENTATIONS

Peer reviewed: International (not complete)

Heterogeneous MS Pathology; Implications for Remyelination Gordon Research Conference on Myelin Barga, Italy

05/1996

Oligodendrocyte Loss and Preservation in Early MS Fourth Altschul Symposium Saskatoon, Saskatchewan, Canada

06/1996

Bcl-2 Expression in Oligodendrocytes from Multiple Sclerosis Lesions European Charcot Foundation Vienna, Austria

07/1996

Symposium on Remyelination in Multiple Sclerosis. Presentation on Clinical Trials on MS Patients with Fixed Neurological Deficits. European Charcot Foundation Vienna, Austria

07/1996

Monoclonal antibodies and their effects on experimental remyelination. European Charcot Foundation Madrid, Spain

10/1997

26

Demographic and Clinical Findings in 20 Cases of Pathologically-Diagnosed Corticobasal Degeneration The Movement Disorders Society's 6th International Congress of Parkinson's Disease and Movement Disorders Barcelona, Spain

06/2000

Steroid-Responsive Encephalopathy Associated with Thyroid Autoimmunity: Outcome with Immunomodulatory Therapy. 17th World Congress of Neurology London, England, United Kingdom

06/2001

The Pathology and Immunopathology of Acute MS Lesions MAGNIMS Clinically Isolate Syndrome Workshop London, United Kingdom

01/2004

An Association Study of HLA Class II Allegles and Immunopathological Patterns in Multiple Sclerosis Annual ECTRIMS Meeting Vienna, Austria

10/2004

Gender Differences in Immunopathological Patterns of Multiple Sclerosis Poster ECTRIMS Vienna, Austria

10/2004

Homogeneity versus heterogeneity in MS: Stage-dependent or patient-dependent European Committee for Treatment and Research in MS Prague, Czech Republic

10/2007

Neuromyelitis Optica: Pathology and Pathogenesis American Academy of Neurology Toronto, ON, Canada

04/2010

What Pathology Tells us about MS Disease Course and Therapy CMSC 25th Annual Meeting Montreal, PQ, Canada

07/2011

American Academy of Neurology (AAN) Vancouver, British Columbia, Canada Title: Back to the Basics: From the Microscope to the Bedside

4/15-21, 2016

International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Berlin, Germany. Title: Spinal cord pathology in MS and NMOSD vs normal microanatomy

05/18-20/2017

Seoul National University Hospital Seoul, South Korea Title: Neuromyelitis Optica: A Systemic Autoimmune Channelopathy

06/28, 2017

27

Hospital of National Cancer Center Seoul, South Korea Title: Granulocytic Recruitment in NMO Contact: Ho Jin Kim, M.D., Ph.D.

06/30, 2017

Visit to Samsung Medical Center Seoul, South Korea Title of first lecture: Neuromyelitis Optica: Pathology and Pathogenesis of an Autoimmune Systemic Channelopathy

07/3, 2017

Visit to Samsung Medical Center Seoul, South Korea Title of second lecture: Granulocytic Recruitment in NMO

07/3, 2017

7th Joint Ectrims - Actrims Meeting Paris France Title: Evolution of MS Plaques

10/ 20, 2017

MS Pathological Heterogeneity: New Insights and Directions National Cancer Center of Korea Seoul, South Korea

06/12, 2018

MS Pathological Heterogeneity: New Insights and Directions Seoul National University

Seoul, South Korea

06/14, 2018

ECTRIMS – 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis Berlin, Germany Title: Pathology of radiologically isolated syndrome

10/10-12, 2018

Peer-reviewed: National (not complete)

A Comparison of Cryoprobe and Crush Lesions in the Rat Sciatic Nerve National Neuroscience Meeting Phoenix, Arizona

01/1989

Electrical Field Effects on Crushed Nerve Regeneration National Neuroscience Meeting Phoenix, Arizona

01/1989

Clinical, Serological, and Oncological Profiles of Patients Seropositive for Type 1 Anti-neuronal Nuclear Autoantibodies American Academy of Neurology Washington, District of Columbia

01/1994

Gastrointestinal Dysmotility Spectrum in Patients Seropositive for Paraneoplastic Type 1 Anti-neuronal Nuclear Autoantibodies Fifth International Symposium on the Autonomic Nervous System Rochester, Minnesota

01/1994

28

Development of an Animal Model of Multifocal Inflammatory Demyelination Induced by 5-Fluorouracil and Levamisole American Academy of Neurology Seattle, Washington

01/1995

Clinical and Oncological Profiles of Patients Seropositive for Type 2 Anti-neuronal Nuclear Autoantibodies American Academy of Neurology San Francisco, California

01/1996

Oligodendrocyte Loss and Preservation in Early Multiple Sclerosis American Neurological Association Miami, Florida

01/1996

Loss of Myelin-Associated Glycoprotein in Active Multiple Sclerosis Lesions Associated with Oligodendrocyte Apoptosis Myelin Satellite Meeting; Frontiers of Myelin Biology and Demyelinating Disease Mystic, Connecticut

07/1997

Immunopathology of Multiple Sclerosis American Society of Neuropathology Minneapolis, Minnesota

06/1998

Humoral Mechanisms in the Pathogenesis of Neuromyelitis Optica American Academy of Neurology San Diego, California

05/2000

Antibodies to Myelin Proteins in Patients with Severe Attacks of Demyelinating Disease Who Undergo Therapeutic Plasma Exchange American Academy of Neurology Philadelphia, Pennsylvania

05/2001

Anti-neuronal Nuclear Autoantibody-Type 2 (ANNA-2 or' Anti ri'): Neurological, Oncological, and Serological Accompaniments and Frequency American Academy of Neurology Philadelphia, Pennsylvania

05/2001

Steroid-Responsive Encephalopathy Associated with Thyroid Autoimmunity American Academy of Neurology Philadelphia, Pennsylvania

05/2001

Heterogeneity of Multiple Sclerosis Pathogenesis: Implication for Diagnosis and Therapy American Academy of Neurology Philadelphia, Pennsylvania

05/2001

29

Aspirin for Multiple Sclerosis-Related Fatigue. Results of a Double-Blind, Placebo-controlled Study American Academy of Neurology Denver, Colorado

04/2002

Steroid-Responsive Encephalopathy Associated with Thyroid Autoimmunity. Clinical and Laboratory Findings American Academy of Neurology Denver, Colorado

04/2002

The Pathology of Primary Progressive MS Round Table Discussion on Primary Progressive MS Houston, Texas

11/2002

A Marker Autoantibody Discriminates Neuromyelitis Optica from Multiple Sclerosis American Academy of Neurology Hawaii

04/2003

Identification of a Marker Autoantibody of Neuromyelitis Optica American Academy of Neurology Hawaii

04/2003

The Clinical Course of Biopsy-Proven Demyelinating Disease and Comparison with a Population-based MS Prevalence Cohort Platform ACRTRIMS: American Committee for Treatment of Research in MS San Francisco, California

10/2003

32CCRS Mutation and the Course of Histopathology of MS Poster ACTRIMS San Francisco, California

10/2003

Amphiphysin Autoantibody: Neurological, Oncological, Pathological, and Serological Accompaniments in 60 Patients Platform American Academy of Neurology San Francisco, California

04/2004

Pathological Subtype of MS Predicts Treatment Response to Therapeutic Plasma Exchange Platform American Academy of Neurology San Francisco, California

04/2004

Neurological Manifestations of Systemic Disease: Other American Academy of Neurology San Francisco, California

04/2004

30

Anti Myelin Antibodies: Frequency, Stability, and Clinicopathologic Correlations Platform ACTRIMS: American Committee for Treatment and Research in MS Toronto, Ontario, Canada

10/2004

Update on the International MS Lesion Project Platform ACTRIMS: American Committee for Treatment and Research in MS Toronto, Ontario, Canada

10/2004

Brain Abnormalities in Patients with Neuromyelitis Optica (NMO) Platform American Academy of Neurology Miami Beach, Florida

04/2005

Neuromyelitis Optica Diagnostic Criteria Revisited: Validation and Incorporation of the NMO-IgG Serum Autoantibody American Academy of Neurology Miami Beach, Florida

04/2005

Basic Science Subcommittee Santa Monica, California

01/2008

NMO Roundtable Conference NMO Roundtable Conference Los Angeles, California

11/2009

CMSC Consensus Meeting CMSC Consensus Meeting Short Hills, New Jersey

03/2010

NMO Roundtable NMO Roundtable Los Angeles, California

11/2010

NMO Roundtable Conference NMO Roundtable Conference Los Angeles, California

02/2012

NMO Update 04/2012 American Academy of Neurology

New Orleans, Louisiana

Gray Matter Pathology in MS 06/2012 CMSC 26th Annual Meeting

San Diego, California

Neuromyelitis Optica: Scientific & Clinical Update 03/2013 American Academy of Neurology


MS Overview I: Basic and Translational Science 03/2013 American Academy of Neurology

31


Progressive MS Pathology: Role of Cortical Lesions, Deep Gray 10/2013 Structures, and Spinal Cord

American Neurological Association

New Orleans, Louisiana

New Insights and Future Directions in MS Pathology

CMSC 28th Annual Meeting 05/2014

Dallas, Texas

CMSC Annual Meeting of Consortium of MS Centers. 05/25/2017 New Orleans, LA

Title: Neuromyelitis Optica: Pathogenic Insights on an

Autoimmune AQP4 Channelopathy

Evolution of the MS Plaque: Pathogenic and Treatment Implications 2018 Alpers Lecture

May 24, 2018

Jefferson University

Philadelphia, Pennsylvania

2018 Alpers Lecture May 25, 2018 Jefferson University

Philadelphia, Pennsylvania

Title: Neuromyelitis Optica: A Systemic Autoimmune

Channelopathy

2018 Annual Meeting of the Consortium of Multiple Sclerosis Centers, John Whitaker Memorial Lecture, Nashville, TN Title: New Insights into MS Pathology Using Synchrotron X-ray Fluorescence Imaging (SXRF)

5/31/2018 – 6/1/2018

ACTRIMS Young Scientist Summit in Clinical Neuroimmunology Savannah, GA Title: Neuropathology of MS

1/11/19

Neurology in Clinical Practice 2019 Honolulu, HA Title: From the Microscope to Bedside: Insights on the Spectrum of CNS Inflammatory Demyelinating Diseases

7/19/19

GRIT for Women in Medicine: Growth, Resilience, Inspiration, & Tenacity 2019 Ojai CA Title: Discovering your Leadership Style

9/19/19

Regional (not complete)

MS Lesion Project - Examining MS Lesions to See Why People Experience MS Differently National Multiple Sclerosis Society Minnesota Chapter Research Symposium Rochester, Minnesota

04/2001

32

Differential Diagnosis of MS: Conditions that Mimic MS Minnesota Society of Neurological Sciences Fall Conference and Annual Meeting Bloomington, Minnesota

11/2001

Update Mini MS Symposium Minneapolis, Minnesota

05/2008

CMSC Course: Neuromyelitis Optica and other CNS Demyelinating Diseases. “Pathological Features of Demyelinating Disease: Can pathology lead to specific diagnosis?

5/282015

CLINICAL INTERESTS

Evaluation and management of patients with immune-mediated disorders of the nervous system, with emphasis on multiple sclerosis, neuromyelitis optica, paraneoplastic disorders, myasthenia gravis, neurosarcoidosis, Stiff person’s syndrome, and CNS vasculitis.

RESEARCH INTERESTS

1. Investigation of the neuropathological patterns and mechanisms of demyelination and

oligodendroglial pathology in early MS.

2. Correlation of MS neuropathology with clinical, paraclinical and genetic parameters.

3. Natural history and immunopathogenesis of fulminant demyelinating disease.

4. Neuromyelitis Optica: Mechanisms of Astrocyte Dysfunction

5. Conduction of clinical trials using novel immunotherapies in multiple sclerosis and neuromyelitis optica.

6. Characterization of novel antigens in paraneoplastic disorders, and study their clinical and oncological correlations.

7. X-ray Fluorescence Imaging to characterize Metal Homeostasis in Demyelinating Diseases

8. Ex vivo Image analysis of MS Pathology

9. Mechanisms of Cortical Pathology in MS

RESEARCH GRANTS AWARDED

ACTIVE Grants Industry

33

Principal Investigator

Amendment 3: A Synchrotron X-ray Fluorescence Based Approach to Examine the Role of Metals in Multiple Sclerosis Tissues Annual Direct: $487,039 Biogen Idec.

04/01/2014 –

08/31/2020


Tissue Pathogenesis of Progression in Multiple Sclerosis Annual Direct: $750,000 Development

03/01/2018– 02/28/2021

Federal

Co-Investigator (PI: LongJun Wu)

The role of microglia in neuromyelitis optica Annual Direct: $351,790 NIH - R01NS 110949-1

09/01/2019- 08/31/2024

Co-Investigator (PI: Eckel Passow)

Diagnosis of indeterminate brain lesions using MRI-based machine learning and polygenic risk models Annual Direct: $499,996 National Institute of Neurological Disorders and Stroke NS 113803

09/01/2019 08/31/2024

Co-Investigator (PI: Flanagan, E.)

Myelin oligodendrocyte glycoprotein antibody disease: incidence, prevalence, outcome prediction and immunopathology Annual Direct: $250,480 National Institute of Neurological Disorders and Stroke R01NS 113828-1

09/01/2019 08/31/2024

Foundation


Metabolic Dysfunction in MS Pathogenesis and Disease Progression CA-1508-06163 Annual Directs: $150,000 National Multiple Sclerosis Society

07/01/2016 -

06/30/2021

Principal FTIR and XRF Microscopy of MS Lesions 6/2018-5/2021

Investigator Annual Direccts: $250,000 Kingsland Foundation

Completed Grants

Federal (NIH)

Co- Investigator

Cortical Lesions as Determinants of White Matter Lesion Formation and Cognitive Abnormalities in MS. Funded by Department of Defense. (W81XWH-13-1-0098)

05/2013 - 04/30/16

34

Program Director/ Principal Investigator

Mast Cells in Neuromyelitis Optica. Funded by TBN1/CMSDD-1 Park Grant

06/01/2014 – 05/31/2015

Program Director / Principal Investigator

Mechanisms of Multiple Sclerosis Tissue Pathology. Funded by National Institute of Neurological Disorders and Stroke. (R01 NS 49577-07) (NCE)

07/2009 - 04/2014


Cortical Demyelination and Leukocyte Trafficking in MS. Funded by National Institute of Neurological Disorders and Stroke. (P50 NS 38667-15)

01/2010 - 12/2014


The Genetic Determinants of Pathologic Heterogeneity in MS. NIH NINDS. NS049577-01A2

04/01/2016 – 03/31/2009


Mechanisms of Multiple Sclerosis Tissue Pathology. Funded by National Institute of Neurological Disorders and Stroke. (R01 NS 49577)

05/2006 - 02/2009

Co- Investigator

Plasma Exchange in Severe Demyelinating Disease. Funded by National Institute of Neurological Disorders and Stroke. (R01 NS 32774)

01/1995 - 12/2001

Co- Investigator

Developmental Research Program in: Lymphoma SPORE. Funded by National Cancer Institute. (P50 CA 97274)

07/2002 - 06/2007

Associate Director

General Clinical Research Center. Funded by National Center for Research Resources. (M01 RR 00585)

12/1994 - 09/2006

Associate Director

GCRC Competitive Renewal (2/1/04): Program Directors Only. Funded by National Center for Research Resources. (M01 )

12/2004 - 11/2005

Foundation


Reactive astrocyte-mediated disruption of neuronal and glial function as a therapeutic target in demyelinating diseases of the central nervous system. Annual Directs: $100,000 Mayo Clinic Development

01/02/2017 – 01/01/2019

35


BRIGHT-MS Study: Utility of ADC maps in patients with acute demyelinating lesions Annual Direct: 132,830 Mallinckrodt Medical, Inc.

05/02/2016 – 12/11/2018


Synergistic Interactions between Astrocytes, Eosinophils and AQP4-IgG in NMO. Funded by Guthy Jackson Charitable Foundation. (NCE)

07/2010 - 03/2014


Mechanisms of JC virus reactivation and pathogenesis in Multiple Sclerosis. Funded by National Multiple Sclerosis Society. (R21 RG4523-A-1)

04/2011 - 03/2014


Project #2A - Determining the Pattern of Pathology in Acute Multiple Sclerosis in: Myelin Repair in Multiple Sclerosis. Funded by Applebaum Foundation.

04/1997 - 03/2004


Multiple Sclerosis Lesion Project. Funded by National Multiple Sclerosis Society. (RG3185-B-3)

04/2005 - 06/2013


Immunopathological & Molecular Mechanisms of Demyelination in Multiple Sclerosis. Funded by National Multiple Sclerosis Society.

07/1998 - 06/2000


Multiple Sclerosis Lesion Project. Funded by National Multiple Sclerosis Society. (RG3185-B-3)

04/2000 - 03/2005

Co- Investigator

Hilton Foundation. Funded by Conrad N Hilton Foundation.

01/2005 - 12/2007

Co- Investigator

Development and Validation of Aquaporin Autoimmunity Models in: Genetics of Neuromyelitis Optica and Molecular Basis of Susceptibility. Funded by Guthy Jackson Charitable Foundation.

10/2008 - 09/2011

Industry


Amendment 3: Clinical and Radiographic Correlates of Early MS Pathology (Protocol No. CFTY720DUS37T); $1.5 million/3 years Novartis.

04/28/2014 – 12/08//2018

36


The Mechanistic Relationship Between Early Complement Factor Production and Granulocyte Recruitment to the CNS in Response to NMO IgG Stimulation of Astrocytes. Project total: $447,949 Alexion Pharmaceuticals, Inc.

07/01/2014 – 12/15/2018

Co-Program Director / Principal Investigator

Teriflunomide-Medicated Suppression of Astrocyte Reactivity as a Therapeutic Intervention in Neuromyelitis Optica and Other Astrocytopathies Annual Direct: $195,155 Sanofi-Synthelabo Resarch.

09/30/2014-09/2018


Therapeutic Targeting of Mast Cells in Chronic Inflammatory Autoimmune Diseases. Funded by Kolltan Pharmaceuticals, Inc.

01/2013 - 06/2013

Co- Investigator

Phase III, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of Betaseron in Patients with Secondary-Progressive Multiple Sclerosis. Funded by Berlex Laboratories, Inc. (Berlex #7)

07/1995 - 06/1998

Consultant Linomide Study - Mayo Rochester Clinical Site Budget. Funded by Pharmacia Pharmaceuticals. (Kabi #6)

09/1995 - 08/1999

Mayo Clinic

Co- Investigator

Cortical Plaque-White Matter Plaque Connectivity Imaging in Multiple Sclerosis. Funded by High-Impact Pilot and Feasibility Award (HIPFA).

12/2012 - 11/2014

Co-Program Director / Principal Investigator

Individualized assessment of NMO patient microglial response to high-titer NMO IgG. Funded by SGP - Small Grants Program <$10K.

10/2012 - 10/2014


Bridge award: Molecular mechanisms of dying- back Oligodendrogliopathy. (CR75)

01/1998 - 12/1999


Involvement of the Oligodendrocyte in the Pathogenesis of Early Multiple Sclerosis. Funded by Mayo CR20 Funding.

07/1996 - 06/1998

37

MAYO IRB PROTOCOLS

Active Principal Investigator

Provision of human sera and cerebrospinal fluid from patients with neurological diseases (with and without neural autoantibodies) for laboratory based analyses

10/30/2018 – 10/29/2021


The Clinico-Pathological Correlates of the Multiple Sclerosis Lesion". Norvartis. (2067-99)

01/2000 - 06/06/2020


The Genetic Determinants of Pathologic Heterogeneity in MS - protocol. NIH NINDS. (06-002348)

05/2006 - 02/21/2020


MS Lesion Project Biospecimen Resource (MSLP-BR). principal benefactor. (13-004814)

02/2014 – 02/06/2020

Co-Principal Investigator

Mechanisms of immune-mediated activation of astrocytes. Department of Neurology funding. (13-007467)

10/2013 - 03/25/2020

Co- Investigator

"Sera Kallikrein Levels in MS Patients". (2238- 04)

11/2004 – 01/02/2020

Co- Investigator

Mechanisms of Eosinophil and Immune Cell Activation in Allergic Diseases. NIH. (06- 004868)

09/2006 – 08/06/2019

Co- Investigator

Non-Ambulatory Impairment in Benign vs. Non- benign Multiple Sclerosis. National Multiple Sclerosis Society. (06-005166)

10/2006 - 03/05/2020

Co- Investigator

Central Nervous System (CNS) Inflammatory Diseases Repository. Guthy Jackson Charitable Foundation. (08-007846)

02/2009 - 11/2014

Co- Investigator

Pontine Encephalitis with Perivascular Enhancement Responsive to Steroid (PEPERS)-NOW TERMED CLIPPERS. No funds requested. (09-001777)

04/2009 - 01/31/2020

Co- Investigator

Cortical Lesions as Determinants of White Matter Lesion Formation and Cognitive Abnormalities in MS. Department of Defense through the CDMRP. (13-003115)

05/2013 – 03/11/2020

Administrative Cancer and Autoimmune Diseases Repository

06/11/2019 – 06/10/2020

38

Completed

Co- Investigator

Cortical Lesion Imaging and Lesion Based Tractography in Pediatric and Adult Relapsing- Remitting Multiple Sclerosis (RRMS). Neurology Discretionary Funds, CTSA fund. (11-006636)

11/2011 – 09/24/2015


CVO-Related Symptoms in NMO: Relevance to Disease Pathogenesis. We anticipate submitting to the Neurology Research Committee a request for $5000 to support statistical costs related to this study. (11- 001981)

05/2011 - 03/2015


Neuromyelitis Optica and Spectrum of Mood Disorders: Frequency, Clinical and Paraclinical Correlates. $5,000 of Neurology departmental discretionary funds. (11-003414)

09/2011 - 09/2014


"A Randomized, Double-Blind, Placebo- Controlled Study of AVONEX (Interferon Beta- 1a) in the Treatment of Subjects at High Risk for Development of Multiple Sclerosis Following the First Onset of an Isolated Demyelinating Event #C95-812, Vers. (357-96)

05/1996 - 03/2001


Molecular Mechanisms of Dying-Back Oligodendrogliopathy in Demyelinating Disease. (1604-97)

11/1997 - 09/2001


Immunopathological and Molecular Mechanisms of Demyelination in Multiple Sclerosis. (130-98)

01/1998 - 12/2001

Co- Investigator

BL01-3112: To Determine if Betaseron Affects the Progression of Secondary-Progressive Multiple Sclerosis. (545-95)

07/1995 - 04/2001

Co- Investigator

A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Roquinimex (Linomide) in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis. (694- 95)

09/1995 - 06/1999

Co- Investigator

Clinical Study Protocol No. A96002i: Phase II Study of Hu23F2G in Acute Exacerbations of Multiple Sclerosis. (242-97)

02/1997 - 05/2000

Co- Investigator

A Pilot Study of Aspirin for Fatigue in Multiple Sclerosis. (1516-97)

10/1997 - 10/2001

39

Co- Investigator

"Teva Neuroscience LCCPROMiSe Trial 9008 - A Multi-National, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Glatiramer Acetate for Injection in Primary-Progressive Multiple Sclerosis. (25-99)

03/1999 - 03/2004

Co- Investigator

A Safety Trial of Adding Copaxone (glatiramer acetate) Injections to Patients with Relapsing- Remitting Multiple Sclerosis (MS) Receiving Avonex (Interferon b 1-a) Therapy (CombiRx). (297-99)

03/1999 - 02/2003

Co- Investigator

"General Clinical Research Center". (1094-98) 06/1999 - 10/2007

Co- Investigator

"Protocol 21125, An Open Label, Randomized, Multicenter, Comparative Parallel Group Study of Rebif 44 mcg Administered 3 Times Per Week by Subcutaneous Injection Compared with Avonex 30 mcg Administered Once Per Week by Intramuscular Inject. (1659-99)

10/1999 - 09/2002

Co- Investigator

Pathogenesis of Primary Central Nervous System Non-Hodgkin's Lymphoma (PCNSL): CNS Antigen Identification. (1819-99)

11/1999 - 12/2004

Co- Investigator

Neurological and Oncological Correlations in Patients Seropositive for Type 2 Anti-Neuronal Autoantibodies (ANNA-2, anti-Ri). (379-00)

02/2000 - 02/2002

Co- Investigator

A 12 Week, Multicenter, Randomized, Double- Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride (E2020) in the Treatment of Cognitive Impairment in Patients with Multiple Sclerosis. (1225-00)

08/2000 - 05/2003

Co- Investigator

"Autoimmune Encephalopathies: The Mayo Experience". (1664-00)

09/2000 - 02/2008

Co- Investigator

Identification of a Disease Specific IgG Marker in Serum and Spinal Fluid of Patients with Neuromyelitis Optica (Devic's Disease). (614- 01)

03/2001 - 08/2004

Co- Investigator

"Clinicopathologic Analyses in Patients with Clinically- and/or Pathologically-Diagnosed Corticobasal Degeneration". (2006-02)

10/2002 - 04/2011

40

Co- Investigator

"CAMMS223: A Phase II, Randomized, Open- Label, Three Arm Study Comparing Low-and High-Dose CAMPATH (MABCAMPATH) and High-Dose Rebif in Patients with Early, Active Relapsing-Remitting Multiple Sclerosis". Genzyme. (619-03)

06/2003 - 11/2010

Co- Investigator

"Neuromyelitis Optica (NMO)-IgG: A Clinical- Serological Study". (1559-03)

08/2003 - 08/2008

Co- Investigator

"Creation of an NMO-IgG Plasma Database". (1560-03)

10/2003 - 08/2007

Co- Investigator

"Brain Involvement in Neuromyelitis Optica. A Clinico-Radiological Study.". (1463-04)

07/2004 - 04/2008

Co- Investigator

MRI Predictors of Plasma Exchange Therapy Response. (1582-04)

08/2004 - 08/2005

Co- Investigator

"Radiation Therapy and Multiple Sclerosis". (2360-04)

11/2004 - 11/2011

Co- Investigator

"Multiple Sclerosis and Anterior Horn Cell Disease: A Review of the Mayo Clinic Experience". (602-05)

03/2005 - 04/2014

Co- Investigator

"NMO-IgG in Pediatric Demyelination; Clinical Correlates". (2464-05)

12/2005 - 10/2008

Co- Investigator

Radiographic and Clinico-Serological Factors Associated with Therapeutic Plasma Exchange in Patients with CNS Idiopathic Inflammatory Demyelinating Diseases: A Retrospective Review". Mayo Neurology Department Small Grant Award. (120-06)

01/2006 - 08/2011

Co- Investigator

Effect of AQP4-IgG on neuronal electrophysiology. (07-004739)

10/2007 - 08/2009

Co- Investigator

An open label study of the effects of Eculizumab in neuromyelitis optica. Alexion Pharmaceuticals Inc. (09-001240)

04/2009 - 07/2013

Co- Investigator

A retrospective study of patients with neuromyelitis optica treated with azathioprine. No funds. (09-008370)

12/2009 - 10/2011

Co- Investigator

Computational Imaging Markers Distinguishing Tumefactive Multiple Sclerosis. Bonner scholarship for co-investigator Kelm. The study will use resources of the Radiology Informatics Laboratory. (11-008819)

01/2012 - 12/2012

41

PATENTS

Title: Marker for Neuromyelitis Optica Date issued09/06/2006 Patent number: US 7101679 Inventors: Vanda Lennon, Thomas Kryzer, Brian Weinshenker, Claudia Lucchinetti

BIBLIOGRAPHY

Full Length Articles

1. Rodriguez M, Lucchinetti CF, Clark RJ, Yaksh TL, Markowitz H, Lennon VA. Immunoglobulins and Complement in Demyelination Induced in Mice by Theiler's Virus. J Immunol 1988; 140:800-806. PubMed PMID:3339243.

2. Kerns J, Braverman B, Mathew A, Lucchinetti CF. A Comparison of Cryoprobe and Crush Lesions in the Rat Sciatic Nerve. Pain 1991; 47:31-39. PubMed PMID:1377636

3. Kerns J, Lucchinetti CF. Electrical Field Effects in Crushed Nerve Regeneration. Exper Neurol; 1992; 117:71-80.

4. Lucchinetti CF, Brück WB, Rodriguez M, Lassmann H. Distinct Patterns of Multiple Sclerosis Pathology Indicate Heterogeneity in Pathogenesis. Brain Path 1996; 6:259-274. PubMed PMID:8864283

5. Lassmann H, Brück WB, Lucchinetti CF, Rodriguez M. Remyelination in Multiple Sclerosis. Mult Scler 1997; 3:133-136.

6. Lucchinetti CF, Noseworthy JH, Rodriguez M. Promotion of Endogenous Remyelination in Multiple Sclerosis. Multiple Sclerosis 1997; 3:71-75. PubMed PMID:9291156.

7. Lucchinetti CF, Rodriguez M. The Controversy Surrounding the Pathogenesis of the Multiple Sclerosis Lesion. Mayo Clin Proc 1997;72:665-678. PubMed PMID: 9212772.

8. Lucchinetti CF, Kimmel DW, Pavelko K, Rodriguez M. 5-Fluorouracil and Levamisole Exacerbate Demyelination in Susceptible Mice Infected With Theiler’s Virus. Exper Neurol 1997;147:123-129. PubMed PMID: 9294409

9. Lucchinetti CF, Kiers L, O'Duffy A, Gomez M, Cross S, Leavitt J, O'Brien P, Rodriguez M. Risk Factors for Developing Multiple Sclerosis Following Childhood Optic Neuritis. Neurology 1997; 49:1413-1418. PubMed PMID: 9371931.

10. Weinshenker B, Lucchinetti CF. Acute Leukoencephalopathies: Differential Diagnosis and Investigation. Neurologist 1998; 4(3): 148-166.

11. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Multiple Sclerosis: Lessons from

Neuropathology. Seminars in Neurology 1998;18(2): 337-349. PubMed PMID: 9817538.

12. Petty GW, Engel AG, Younge BR, Duffy J, Yanagihara T, Lucchinetti CF, Bartleson FD, Rodriguez MR, Kasperbauer FL. Retinocochleocerebral vasculopathy. Medicine 1998; 77:12-40.

42

13. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and Oncologic Profiles of Patients Seropositive for Type 1 Antineuronal Nuclear Autoantibodies. Neurology 1998; 50:652-657. PubMed PMID: 9521251.

14. Drescher KM, Rivera-Quinones C, Lucchinetti CF, Rodriguez M. Failure of Treatment with

Linomide or Oral Myelin Tolerization to Ameliorate Demyelination in a Viral Model of Multiple Sclerosis. J Neuroimmunol 1998; 88:111-119. PubMed PMID: 9688332

15. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti CF, Folcik VA, Qin S, Sellebjerg F,

Strieter RM, Frederiksen JL, Ransohoff RM. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103(6):807-815.

16. Auger RG, Windebank AJ, Lucchinetti CF, Chalk CH. Role of the Blink Reflex in the Evaluation of Sensory Neuronopathy. Neurology 1999; 53:407-408. PubMed PMID: 10430436

17. Kuhlmann T*, Lucchinetti CF*, Zettle UK, Bitsch A, Lassmann H, Bruck W. Bcl-2 Expressing Oligodendrocytes in Multiple Sclerosis Lesions. Glia 1999; 28(1):34-39

*Both authors contributed equally to content of the manuscript.

18. Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M. A Randomized Trial of Plasma Exchange in Acute CNS Inflammatory Demyelinating Disease. Ann Neurol 1999; 46(6):878-886. PubMed PMID: 10589540

19. Lucchinetti CF, Brueck W, Rodriguez M, Parisi J, Scheithauer B, Lassmann H. A

Quantitative Analysis of Oligodendrocytes in Multiple Sclerosis Lesions: A Study of 113 cases. Brain 1999;122:2279-2295.

* Cited on cover of journal

20. Lucchinetti CF, Bruck B, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of Multiple Sclerosis Lesions: Implications for the Pathogenesis of Demyelination. Ann Neurol 2000; 47:707-717.

*Subject of lead editorial of journal

21. Jacobs LD, Beck RW, Simon JH, et al. The CHAMPS Study Group. Intramuscular Interferon Beta-1-a Therapy Initiated During A First Demyelinating Event in Multiple Sclerosis. New Engl J Med 2000;343:898-904.

22. Noseworthy JH, Lucchinetti CF, Rodriguez M, Weinshenker B. Medical Progress. Multiple Sclerosis. New Engl J Med 2000; 343:938-952.

23. Wingerchuk DM, Lucchinetti CF, Noseworthy JH. Multiple Sclerosis. Current Pathophysiological Concepts. Lab Invest 2001; 81:263-281. PubMed PMID:11310820.

24. Lassmann H, Brück W, Lucchinetti CF. Heterogeneity of Multiple Sclerosis Pathogenesis:

Implications for Diagnosis and Therapy. Trends Mol Med 2001; 7:115-121. PubMed PMID: 11286782.

25. Bitsch A, Kuhlmann T, Stadelmann C, Lassmann H, Lucchinetti CF, Bruck W. A

Longitudinal MRI Study of Histopathologically Defined Hypointense Multiple Sclerosis Lesions. Ann Neurol 2001; 49:793-796.

43

26. Lucchinetti CF, Bruck W, Noseworthy J. Multiple Sclerosis: Recent Developments in Neuropathology, Pathogenesis, Magnetic Resonance Imaging Studies and Treatment. Curr Opin Neurol 2001; 14:259-269.

27. O’Connor P, Fleming P, Gray T, Jacobs L, Miller C, Munschauer F, Kinkel RP, Bolibrush D, Cohen J, Freedman M, Webb U, Rabinowicz H, Metz LM, Patry D, Yeung M, Peters S, Hashimoto S, Morrison W, Oger J, Panitch H, Costello K, Bever C, Stuart W, Court D, Stuart D, Beck R, et al (Lucchinetti CF). Interferon beta-1 a for Optic Neuritis Patients at High Risk for Multiple Sclerosis. [Article] Am J Ophthalmol 2001; 132:463-471.

28. Scarisbrick IA, Blaber SI, Lucchinetti CF, Genain CP, Blaber M, Rodriguez M. Activity of a newly identified serine protease in immune-mediated demyelination. Brain. 2002; 125:1-14. PubMed PMID: 12023317

29. Targonski PV, Schiebel N, Lucchinetti CF. Minocycline-Associated Idiopathic Intracranial Hypertension In A Patient presenting to the Emergency Department. The Internet Journal of Emergency and Intensive Care Medicine 2002; 6(1).

30. Martínez-Arizala A, Barnes G, Benjamin S, Bowen JD, Cutter N, de Lateur BJ, Dietrich WD,

Dowling MM, Griffin JW, Hummers L, Irani D, Jorens PG, Kaplin AI, Katz JD, Kerr DA, Krishnan C, Levy CE, Lucchinetti CF, Lynn DJ, Mandler RN, McArthur JC, McDonald JW, Morrison L, Pardo-Villamizar C, Pidcock FS, Ransohoff R, et al. Proposed Diagnostic Criteria and Nosology of Acute Transverse Myelitis. Neurology 2002; 59:499-505.

31. Brück W, Lucchinetti C, Lassmann H. The pathology of primary progressive multiple

sclerosis. Mult Scler 2002; 8:93-97.

32. Scarisbrick IA, Blaber SI, Lucchinetti CF, Genain CP, Blaber M, Rodriguez M. Activity of a Newly Identified Serine Protease in Immune-Mediated Demyelination. Brain 2002; 125:1283- 1296.

33. Lucchinetti CF, Mandler R, McGavern D, Bruck W, Gleich J, Ransohoff R, Trebst C,

Weinshenker B, Wingerchuck D, Parisi JP, Lassmann H. A Role for Humoral Mechanisms in the Pathogenesis of Devic’s Neuromyelitis Optica. Brain 2002;125:1450-1461. PubMed PMID:12076996. *Selected for cover of journal and lead editorial

34. O’Connor P, Fleming P, Gray T, Jacobs L, Miller C, Munschauer F, Kinkel RR, Bolibrush D,

Cohen J, Freedman M, Webb U, Rabinowicz H, Metz L, Davis A, Patry D, Hashimoto S, Morrison W, Oger J, Panitch H, Costello K, Bever C, Stuart W, Court D, Stuart D, Tornatore C, Simon J, et al. (Lucchinetti CF). Baseline MRI Characteristics of Patients at High Risk For Multiple Sclerosis: Results From the CHAMPS Trial. Mult Scler 2002; 8:330-338.

35. O’Connor P, Fleming P, Gray T, Jacobs L, Miller C, Munschaner F, Kinkel RP, Bolibrush D, Cohen J, Freedman M, Webb U, Rabinowicz H, Metz LM, Patry D, Yeung M, Peters S, Hashimoto S, Morrison W, Oger J, Panitch H, Costello K, Bever C, Stuart W, Court D, Stuart D, Beck R. et al. (Lucchinetti CF). Predictors of Short-term Disease Activity Following a First Clinical Demyelinating Event: Analysis of the CHAMPS Placebo Group. [Article] Mult Scler 2002; 8:405-409.

36. O’Connor P, Fleming P, Gray T, Jacobs L, Miller C, Munschauer F, Kinkel RP, Bolibrush D,

Cohen J, Freedman M, Webb U, Rabinowicz H, Metz LM, Patry D, Yeung M, Peters S, Hashimoto S, Morrison W, Oger J, Panitch H, Costello K, Bever C, Stuart W, Court D, Stuart D, Simon J. et al. (Lucchinetti CF). MRI Predictors of Early Conversion to Clinically Definite MS in the CHAMPS Placebo Group. Neurology 2002; 59:998-1005.

44

37. Aboul-Enein F, Rauschka H, Kornek B, Stadelmann C, Stefferl A, Bruck W, Lucchinetti CF,

Schmidbauer M, Jellinger K, Lassmann H. Preferential Loss of Myelin-Associated Glycoprotein Reflects Hypoxia-Like White Matter Damage in Stroke and Inflammatory Brain Diseases. [Articles] J Neuropath Exp Neurol 2003;62:25-33.

38. Trebst C, Staugaitis SM, Kivisakk P, Mahad D, Cathcart MK, Tucky B, Wei T, Rani MRS, Horuk

R, Aldape KD, Pardo CA, Lucchinetti CF, Lassmann H, Ransohoff RM. CC Chemokine Receptor 8 (CCR8) in the Central Nervous System is Associated with Phagocytic Macrophages. Am J Pathol 2003; 162:427-438. PubMed Central PMCID: PMC1851139

*39.Pittock SJ, Lucchinetti CF, Lennon VA. Anti-Neuronal Nuclear Autoantibody-type 2 (ANNA- 2, or “Anti RI”): Neurological, Oncological and Serological Accompaniments and Frequency. Ann Neurol 2003; 53:580-587. PubMed PMID: 12730991.

40. Höftberger R, Aboul-Enein F, Ploegh HL, Brueck W, Lucchinetti CF, Rodriguez M, Schmidbauer M, Jellinger K, Lassmann H. Expression of Major Histocompatibility Complex Class I Molecules on the Different Cell Types in Multiple Sclerosis Lesions. Brain Path 2004; 14:43-50.

41. Mahad DJ, Trebst C, Kivisaak P, Staugaitis SM, Tuckey B, Wei T, Lucchinetti CF, Lassmann H, Ransohoff R. Expression of Chemokine Receptors CCR1 and CCR5 Reflects Differential Activation of Mononuclear Phagocytes in Pattern II and Pattern III Multiple Sclerosis Lesions. J

Neuropath Exp Neurol 2004; 63:262-273. PubMed PMID: 15055450.

42. Lucchinetti CF, Brück W. The Pathology of Primary Progressive MS. Mult Scler 2004; 10:S23-S30.

43. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BW. A Serum Autoantibody Marker of Neuromyelitis Optica. Lancet 2004; 364:2106-2112. PubMed PMID: 15589308.

44. Lucchinetti CF. Update on the International Project on Pathologic Correlates in MS. Mult Scler. 2005 Feb; 11(1):99-100. PubMed PMID: 15732277. PubMed PMID: 15661089

45. Lucchinetti CF, Parisi J, Bruck W. The Pathology of Multiple Sclerosis. Neurol Clin 2005; 23:77-105.

46. Wingerchuk DM, Benarroch EE, O’Brien PC, Keegan BM, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M. A Randomized Controlled Crossover Trial of Aspirin for Fatigue in Multiple Sclerosis. Neurology 2005; 64:1267-1269. PubMed PMID: 15824361

47. Stadelmann C, Ludwin S, Tabira T, Guseo A, Lucchinetti CF, Brück W, Lassmann H.

Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis. Brain 2005 128: 979-987. *Cover of journal. PubMed PMID: 15774507.

*48. Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, Kilimann MW, Kim KK, Lennon VA. Amphiphysin Autoimmunity: Paraneoplastic Accompaniments. Ann Neurol 2005; 58:96-107. PubMed PMID: 15984030.

49. Cox A, Coles A, Nagui A, Malik O, Lennon VA, Lucchinetti CF, Compston A. Recurrent myelitis and optic neuritis in a 29-year-old woman. Lancet Neurol 2005; 4:510-516.

45

*50. Keegan M, Konig F, McClelland R, Bruck W, Bitsch A, Panitch H, Lassmann H, Weinshenker B, Rodriguez M, Parisi J, Lucchinetti CF. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366:579-582. PubMed PMID: 16099294.

51. Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, Lucchinetti CF, Wilken J, Karandikar Neuropathy, Hemmer B, Monson Neuropathy, DeKeyser J, Hartung H, Steinman L, Oksenberg JR, Cree BAC, Hauser S, Racke MK. Characterizing the Mechanisms of Progression in Multiple Sclerosis: Evidence & New Hypotheses for Future Directions. Arch Neurol 2005; 62:1345-1356.

52. Kutzelnigg A. Lucchinetti CF. Stadelmann C. Bruck W. Rauschka H. Bergmann M. Schmidbauer M. Parisi JE. Lassmann H. Cortical demyelination and diffuse white matter injury

in multiple sclerosis. Brain 2005; 128:2705-2712. PubMed PMID: 16230320.

*53. Kantarci OH, Morales Y, Ziemer PA, Hebrink DD, Mahad DJ, Atkinson EJ, Achenbach S, De Andrade M, Ransohoff RM, Weinshenker BW, Lucchinetti CF. CCR5Δ32 Polymorphism is not Associated with Age of Onset, Disease Course, Disease Severity and Immunopathology in Multiple Sclerosis. J Neuroimmunol 2005;169:137-43. PubMed PMID: 16182378.

*54. Pittock SJ. McClelland RL. Achenbach SJ. Konig F. Bitsch A. Bruck W. Lassmann H. Parisi JE.

Scheithauer BW. Rodriguez M. Weinshenker BG. Lucchinetti CF. Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease. J Neurol

Neurosurg Psych 2005; 76:1693-1697. PMCID: PMC1739469

*55. Morales Y, Parisi JE, Lucchinetti, CF. The Pathology of Multiple Sclerosis: Evidence for

Heterogeneity. Adv Neurol 2006; 98:27-45. PubMed PMID: 16400825.

56. Weinshenker, BG, Wingerchuk, DM, Pittock, SJ, Lucchinetti, CF, Lennon, VA. NMO-IgG: A

specific biomarker for neuromyelitis optica. Dis Markers 2006; 22:197-206, 2006. PMCID: PMC3851409

57. Fox, RJ, Kivisakk P, Tucky B, Lucchinetti, CF, Fisher E, Rudick R, Ransohoff R. Chemokine

Receptors as Biomarkers in Multiple Sclerosis. Dis Markers 2006; 22: 227-233, 2006. PMCID: PMC3850832

58. Castillo P. Woodruff B. Caselli R. Vernino S. Lucchinetti C. Swanson J. Noseworthy J. Aksamit A. Carter J. Sirven J. Hunder G. Fatourechi V. Mokri B. Drubach D. Pittock S. Lennon V. Boeve B. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006; 63:197-202.

59. Weinshenker, BG, Wingerchuk DM, Vukusic S,, Linbo L, Lucchinetti, C. Pittock S, Lennon V. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006; 59:566-569. PubMed PMID: 16453327

60. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63:390-396. PubMed PMID: 16533966.

*61. Schwartz KM, Erickson BJ, Lucchinetti CF. Pattern of T2 Hypointensity Associated with

Ring Enhancing Brain Lesions can Help to Differentiate Pathology. Neuroradiology 2006;

48:143-149. PubMed PMID: 16447037

46

62. Wingerchuk DM, Lennon V, Pittock S, Lucchinetti C, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66:1485-1489. PubMed PMID: 16717206

63. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006; 63: 964-968. PubMed PMID: 16831965.

*64. Pittock SJ, Lucchinetti CF. Inflammatory Transverse Myelitis Evolving Concepts. Curr Opin Neurol 2006; 19:362-368. PubMed PMID: 16914974.

65. Miller RC, Lachance DH, Lucchinetti CF, Brown PD, Keegan BM, Bhatia S, Rodriguez M. Multiple Sclerosis, Brain Radiotherapy, and Risk of Neurotoxicity: The Mayo Clinic Experience. Int J Radiat Oncol Biol Phys 2006; 66:1178-86. PubMed PMID: 16965867.

65. Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, Sorensen P, Brück W, Lucchinetti CF, Lassmann H. Remyelination is Extensive in a Subset of Multiple Sclerosis Patients. Brain 2006; 129:13165-13172.

66. Lucchinetti CF. Advances in the neuropathology of multiple sclerosis: Evolving pathogenic insights. CONTINUUM Lifelong Learn. Neurol. 2007; 13(5) MULTIPL.SCLEROSIS):86-116.

*68. Hu WT, Kantarci OH, McGrann , Merritt II, Dyck PJB, Lucchinetti CF,Tippmann-Peikert M. Ornithine Transcarbamylase Deficiency Presenting as Encephalopathy During Adulthood Following Bariatric Surgery. Arch Neurol 2007; 64:126-128. PubMed PMID: 17210820.

69. Kutzelnigg A, Faber-Rod JC, Bauer J, Lucchinetti CF, Sorensen PS, Laursen H, Stadelmann C, Brück W, Rauschka H, Schmidbauer M, Lassmann H. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol 2007;17:38-44. PubMed PMID: 17493036.

*70. Pittock SJ , Reindl M, Achenbach S, Berger T, Brück W, Konig F, Morales Y, Lassmann H, Bryant S, Moore SB, Keegan BM, Lucchinetti CF. Myelin Oligodendrocyte Glycoprotein Antibodies in Pathologically Proven Multiple Sclerosis: Frequency, Stability and

Clinicopathologic Correlations. Mult Scler 2007; 13:7-16. PubMed PMID: 17294606.

71. Wingerchuk D, Pittock S, Lennon V, Lucchinetti CF, Weinshenker B. A Secondary Progressive

Clinical Course is Uncommon in Neuromyelitis Optica. Neurology 2007; 68:603- 605. PubMed PMID: 17310032

72. Pirko I, Lucchinetti, CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology 2007; 68:634-642. PubMed PMID: 17325269.

*73. Pittock, S, and Lucchinetti, CF. The pathology of MS: new insights and potential clinical applications. Neurologist 2007; 13:45-56. PubMed PMID: 17351524.

74. Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007; 17:210-218. PMID: PMID17388952

*75. Roemer, SF, Parisi JE, Lennon, VA, Benarroch EE, Lassmann H, Bruck W, Mandler RN,

Weinshenker BG, Pittock, SJ, Wingerchuk DM, Lucchinetti CF. Pattern-specific Loss of Aquaporin 4 Immunoreactivity Distinguishes Neuromyelitis Optica From Multiple Sclerosis. Brain 2007;130:1194-1205. PubMed PMID17282996.

mailto:[email protected]

47

76. Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS, Atkins HL, Azzarelli B, Kolar OJ, Brück W. Autologous hematopoietic stem cell transplantation fails to

stop demyelination and neurodegeneration in MS. Brain 2007; 130:1254-1262. PubMed

PMID17293360.

77. Vana AC, Lucchinetti CF, Le TQ, Armstrong RC. Myelin transcription factor 1 (Myt1) expression in demyelinated lesions of rodent and human CNS. Glia 2007; 55:687-697. PubMed PMID: PMC2789289

*78. Wingerchuk DM, Lucchinetti CF. Comparative Immunopathogenesis of Acute Disseminated Encephalomyelitis, Neuromyelitis Optica, and Multiple Sclerosis. Curr Opin Neurol 2007; 20:343-350. PubMed PMID: 17495631.

79. Jacob A, Matiello M, Wingerchuk, DM, Lucchinetti CF, Pittock, SJ, Weinshenker BG. Neuromyelitis optica: Changing Concepts. J Neuroimmunol 2007;187:126-138. PubMed PMID: 17512987.

80. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker, BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6:805-815. PMID:17706564

81. Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, Lennon VA. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007; 69:2221-2231. PMID:17928579.

82. Lucchinetti C. Pathological heterogeneity of idiopathic central nervous system inflammatory

demyelinating disorders. Curr Top Microbiol Immunol. 2008; 318:19-43. PMID:18219813 83. Pittock, SJ, Lennon VA, de Seze J, MD, Vermersch P, Homburger H, Wingerchuk, D,

Lucchinetti CF, Weinshenker BG. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008; 65:78-83. PMID:18195142.

84. Banwell B, Tenembaum S, Lennon VA, Ursell E, Kennedy J, Bar-Or A, Weinshenker BG, Lucchinetti CF, Pittock SJ. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008; 70:344-352. PMID:18094334.

85. Lucchinetti CF. Multiple sclerosis and the spectrum of CNS inflammatory demyelinating diseases. Semin Neurol. 2008 Feb; 28(1):3-6. PMID:18256982

86. Young NP, Weinshenker BG, Lucchinetti CF. Acute disseminated encephalomyelitis:

current understanding and controversies. Semin Neurol. 2008 Feb; 28(1):84-94. PMID:18256989.

87. Keegan BM, Josephs KA, Parisi JE, Lucchinetti CF, Giannini C, Boeve BF. Sporadic adult- onset leukoencephalopathy with neuroaxonal spheroids mimicking cerebral MS. Neurology 2008; 70:1128-1133. PMID:18287567.

88. Porter AB, Giannini Caterina, Kaufmann Timothy, Lucchinetti CF, Wu Wenting, Decker Paul A, Atkinson John L, O’Neill Brian. Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: A pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma. Ann Neurol 2008; 63:662-667. PMID:18481293.

48

89. Scarisbrick IA, Linbo R, Vandell A, Keegan M, Blaber S, Blaber M, Sneve D, Lucchinetti C, Rodriguez M, Diamandis EP. Kallikreins Are Associated with Secondary Progressive Multiple Sclerosis and Promote Neurodegeneration. Biol Chem 2008; 389:739-745. PMCID: PMC2580060

90. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, Weinshenker BG. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70:2197- 2200. Epub 2008 Apr 23. PMID:18434643.

91. Lucchinetti CF, Gavrilova RH, Metz I, Parisi, JE, Scheithauer BW, Weigand S, Thomsen K,

Mandrekar J, Altintas A, Erickson BJ, König F, Giannini C, Lassmann H, Linbo L, Pittock SJ, Brück W. Clinical and Radiographic Spectrum of Pathologically Confirmed Tumefactive Multiple Sclerosis. Brain 2008; 131:1759-1775. PMCID: PMC2442427.

92. McKeon A , Lennon VA , Lotze T , Tenenbaum S , Ness JM , Rensel M , Kuntz NL , Fryer JP, Homburger H , Hunter J , Weinshenker BG , Krecke K , Lucchinetti CF , Pittock SJ . CNS aquaporin-4 autoimmunity in children. Neurology 2008; 71:93-100, Epub 2008 May 28. PMID:18509092.

93. Rodriguez FJ, Gamez JD, Vrana JA, Theis JD, Giannini C, Scheithauer BW, Parisi J,

Lucchinetti CF, Pendlebury WW, Bergen RH, Dogan A. Immunoglobulin Derived Depositions in the Nervous System: Novel Mass Spectrometry Application for Protein Characterization in Formalin-Fixed Tissues. Lab Invest 2008; 88:1024-1037. PMID:18711355.

94. Hinson SR, Roemer SF, Lucchinetti CF, Fryer JP, Kryzer TJ, Chamberlain JL, Howe CL, Pittock SJ, Lennon VA. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 2008; 205: 2473- 2481; E-pub 2008 Oct. PMCID PMC2571922

95. Quintana F, Mauricio F, Iglesias A, Merbl Y, Lucas M, Basso A, Khoury S, Lucchinetti CF,

Weiner H. Antigen microarrays identify serum autoantibody signatures associated with different clinical forms and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A. 2008; 105:18889-18894; E-pub 2008 Nov; PMCID PMC2596207

96. McKeon A, Lennon VA, Lotze T, Tenenbaum S, Ness JM, Rensel M, Kuntz NL, Fryer JP,

Homburger H, Hunter J, Weinshenker BG, Krecke K, Lucchinetti CF, Pittock SJ. CNS aquaporin-4 autoimmunity in children. Neurology 2008; 71:93-100. PMID:18509092.

*97. Magaña SM, Matiello M, Pittock SJ, McKeon A, Lennon VA, Rabinstein AA, Shuster E,

Kantarci OH, Lucchinetti CF, Weinshenker BG. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurol 2009;72:712-717. PMID:19237699.

*98. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-1189, Mar 31, e-pub ahead of print. PMCID: PMC2677799.

99. Daniels TB, Pollock BE, Miller RC, Lucchinetti CF, Leavitt JA, Brown PD. Radiation-induced optic neuritis after pituitary adenoma radiosurgery in a patient with multiple sclerosis: Case report. J Neurooncol 2009; 93(2);263-267. PMCID: PMC2724634.

49

*100. Magaña SM, Pittock SJ, Lennon VA, Keegan BM, Weinshenker BG, Lucchinetti CF. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease. Arch Neurol 2009 Aug; 66:964-966. PMCID: PMC2742779.

*101. Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti CF, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ. Treatment of Neuromyelitis Optica With Mycophenolate Mofetil: Retrospective Analysis of 24 Patients. Arch Neurol 2009; 66:1128- 1133. PMID:19752302.

102. McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Hinson SR, Kryzer TJ, Lucchinetti CF, Weinshenker BG, Wingerchuk DM, Shuster EA, Pittock SJ. Diagnosis of Neuromyelitis Spectrum Disorders Comparative Sensitivities and Specificities of Immunohistochemical and Immunoprecipitation Assays. Arch Neurol 2009; 66:1134-1138. PMID:19752303.

*103. Staff NP, Lucchinetti CF, Keegan BM. Multiple sclerosis with predominant, severe cognitive

impairment. Arch Neurol. 2009 Sep; 66(9):1139-43. PMID:19752304. PMCID:2763409.

*104. Hu W, Lucchinetti CF. The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol. 2009 Nov; 31(4):439-53. PMID:19779719.

105. McKeon A, Lennon VA, Jacob A, Matiello M, Lucchinetti CF, Kale N, Chan KH, Weinshenker BG, Apiwattinakul M, Wingerchuk DM, Pittock SJ. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve. 2009 Jan; 39(1):87-90. PMID:19086079. DOI:10.1002/mus.21197. PubMed PMID: 19086079.

106. Kale N, Pittock SJ, Lennon VA, Thomsen K, Roemer SF, McKeon A, Lucchinetti CF.

Humoral MS Pathology (Pattern II) is Not Associated with NMO-IgG. Arch Neurol. Author manuscript; available in PMC 2010 October 1.Published in final edited form as: Arch Neurol. 2009 October; 66(10): 1298-1299. PMCID: PMC2767176.

*107. Young NP, Weinshenker BG, Parisi JE, Scheithauer B, Giannini C, Roemer SF, Thomsen

KM, Mandrekar JN, Erickson BJ, Lucchinetti CF. Perivenous CNS Demyelination: Association with Clinically-defined ADEM and Comparison with Pathologically-confirmed MS. Brain 2010 Feb;133 (Pt 2):333-348. Epub 2010 Feb 3. PMCID: PMC2822631.

108. Pittock SJ, Parisi JE, McKeon A, Roemer SF, Lucchinetti CF, Tan KM, Keegan BM, Hunter SF, Duncan PR, Baehring JM, Matsumoto JY, Lennon VA. Paraneoplastic Jaw Dystonia and Laryngospasm with Antineuronal Nuclear Autoantibody Type 2 (Anti-Ri). Arch Neurol 2010 Sep; 67(9):1109-1115. PMID:20837856.

109. Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sorensen PS, Laursen H. Demyelination versus remyelination in progressive multiple sclerosis. Brain. 2010 Oct; 133(10):2983-98. Epub 2010 Sep 20. PMID:20855416. DOI:10.1093/brain/awq250. PubMed PMID: 20855416.

110. Apiwattanakul M, Popescu BF, Matiello M, Weinshenker BG, Lucchinetti CF, Lennon VA,

McKeon A, Carpenter AF, Miller GM, Pittock SJ. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol. 2010 Nov; 68(5):757-61. PMID:21031587. DOI:10.1002/ana.22121. PubMed: PMID20855416.

50

*111. Popescu BFGh, Parisi JE, Cabrera Gomez JA, Newell K, Mandler RN, Pittock SJ, Lennon

VA, Weinshenker BG, Lucchinetti CF. Absence of Cortical Demyelination in Neuromyelitis Optica. Neurol 2010; 75:2103-2109. PMCID: PMC2995539.

112. Jones DT, Mateen FJ, Lucchinetti CF, Jack CR, Welker KM. Default Mode Network Disruption Secondary to a Lesion in the Anterior Thalamus. Arch Neurol 2010; 68:242-247. 2011 Feb; 68(2):242-7. PubMed PMID:20937938.

113. Almekhlafi MA, Clark AW, Lucchinetti CF, Zhang Y, Power C, Bell RB. Neuromyelitis Optica with Extensive Neural Axis Involvement. Arch Neurol 2011; 68:508-512. PMID:21482930.

*114. Bunyan RF*, Popescu BF*, Carter JL, Caselli RJ, Parisi JE, Lucchinetti CF. Childhood )nset Multiple Sclerosis with Progressive Dementia and Pathological Cortical Demyelination. Arch Neurol 2010; 68:525-528. PMCID: PMC3077570

*115. Popescu BFGh, Lennon VA, Parisi JE, Howe CL, Weigand SD, Cabrera Gomez JA, Newell

K, Mandler RN, Pittock SJ, Weinshenker BG, Lucchinetti CF. Neuromyelitis Optica Unique Area Postrema Lesions: Nausea, vomiting and pathogenic implications. Neurology 2011; 76:1229–1237. PMCID: PMC3068006

*116. Popescu BF, Bunyan RF, Parisi JE, Ransohoff RR, Lucchinetti CF. A Case of Multiple Sclerosis Presenting with Inflammatory Cortical Demyelination. Neurology 2011; 76:1705- 1710. PMCID: PMC3100131.

*117. Magaña SM*, Keegan BM, Weinshenker BG, Erickson BJ, Pittock SJ, Lennon VA, Rodriguez M, Thomsen K, Weigand S, Mandrekar J, Linbo L, Lucchinetti CF. Beneficial Plasma Exchange Response in CNS Inflammatory Demyelination. Arch Neurol Jul;68(7):870-8, 2011. Epub 2011 Mar 14. PMCID: PMC3134547.

118. Roemer SF, Scheithauer BW, Varnavas GG, Lucchinetti CF. Tumefactive demyelination and glioblastoma: A rare collision lesion. Clin Neuropathol 2011; 30:186-191. PMID:21726504.

*119. Smith JH, Dhamija R, Moseley BD, Sandroni P, Lucchinetti CF, Lennon VA, Kantarci OH.

NMDA Receptor Autoimmune Encephalitis Presenting with Opsoclonus-Myoclonus: Treatment Response to Plasmapheresis. Arch Neurol, accepted February 25, 2011; 68:1069- 1072. PMID:21825245.

*120. Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, Thapa

P, McKeon A. Azathioprine: Tolerability, Efficacy, and Predictors of Benefit in Neuromyelitis Optica. Neurology 2011; 77:659-666. PMID:21813788.

121. Iorio R, Lucchinetti CF, Lennon VA, Costanzi C, Hinson S, Weinshenker BG, Pittock SJ. Syndrome of Inappropriate Antidiuresis may Herald or Accompany Neuromyelitis Optica. Neurology, accepted July 7, 2011, e-pub October 15, 2011; 77:1644-1646. PMCID: PMC 3198981.

122. Lucchinetti CF, Popescu BFGh, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Brück W, Parisi JE, Scheithauer BW, Giannini C, Weigand SD, Mandrekar J, Ransohoff RM. Inflammatory Cortical Demyelination is Common in Early Multiple Sclerosis. New Engl J Med 2011; 365:2188-2197. PMCID: PMC3282172.

*Named as one of the 10 Best Papers for 2011 by Neurology Today. Subject of editorial in NEJM

51

*123. *Popescu BF, Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol. 2012; 7:185-217. PMID:22313379.

*124. Popescu BFGh, Lucchinetti CF. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurology 2012;12:11. http://www.biomedcentral.com/1471-2377/12/11 PMC PMCID 3315403

*125. Costanzi C, Bourdette D, Parisi JE, Woltjer R, Rodriguez F, Steensma D, Lucchinetti CF. Crystal-storing histiocytosis: An unusual relapsing inflammatory CNS disorder. Multiple Sclerosis and Related Disorders 2012; 1:95-99, PMCID: PMC4612576.

126. Hinson SR, Romero MF, Popescu BFGh, Lucchinetti CF, Fryer JP, Wolburg H, Fallier- Becker P, Noell S, Lennon VA. Molecular Outcomes of NMO-IgG Binding to Aquaporin-4 in Astrocytes. Proc Natl Acad Sci U S A; 1109980108 [pii] 10.1073/pnas.1109980108. PNAS 2012; 109:1245-1250. PMCID: PMC 3268278

127. Filippi M, Rocca MA, Barkhof F, Brück F, Chen JT, Comi G, DeLuca G, De Stefano N,

Erickson BJ, Evangelou N, Fazekas F, Geurts JJG, Lucchinetti C, Miller DH, Pelletier D, Popescu BFGh, Lassmann H. Correlation between pathological and MRI findings in multiple sclerosis: Report from an international consensus workshop. Lancet Neurol 2012; 11:349- 360. PMID:22441196.

*128. Abou Zeid N, Pirko I, Erickson B, Weigand S, Thomsen K, Scheithauer B, Parisi JE, Giannini

C, Linbo L, Lucchinetti CF. Diffusion Weighted Imaging Characterisitics of Biopsy-proven Demyelinating Brain Lesions. Neurology 2012; 78:1655-1662. PMCID 3359505.

129. Quek AML, McKeon A, Lennon VA, Mandrekar JN, Iorio R, Jiao Y, Costanzi C, Weinshenker BG, Wingerchuk DM, Lucchinetti CF, Shuster EA, Pittock SJ. Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol 2012; 69:1039-1043. PMCID 3746965.

130. Brück W, Popescu BFGh., Lucchinetti, CF, Marcovic-Plese S, Gold R, Thal DR, Metz, I. “Neuromyelitis Optica Lesions May Inform Multiple Sclerosis Heterogeneity Debate”, Annals of Neurology 2012; 72;385-394. PubMed: PMID:23034911.

131. Cook, SD, Dowling P, Durelli L, Ford C, Giovannoni G, Halper J. Harris C, Herbert J, Jalbut S, Li D, Lincoln J, Lisak R, Lublin F, Lucchinetti CF, Moore W, Naismith R, Oehninger C, Simon J, Sormani MP, Stone L. MRI as well as Clinical Disease Activity Should be used in the Clinical Classification and Evolution of MS Course: A Report from an International Committee of the Consortium of Multiple Sclerosis Centers. International J MS Care 2012; 14:105-114. PMCID PMC3882992.

132. Popescu BF, Bunyan RF, Guo Y, Parisi JE, Lennon VA, Lucchinetti CF. Evidence of aquaporin involvement in human central pontine myelinolysis. Acta Neuropathol Commun. 2013; 1(1):40. Epub 2013 Jul 25 PMID:24252214. PMCID:3893459.

133. Tutuncu M, Tang J, Zeid NA, Kale N, Crusan DJ, Atkinson EJ, Siva A, Pittock SJ, Pirko I,

Keegan BM, Lucchinetti CF, Noseworthy JH, Rodriguez M, Weinshenker BG, Kantarci OH. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler J 19:188-198, 2013. PMC: PMCID 4029334

134. Iorio R, Lucchinetti CF, Lennon VA, Farrugia G, Pasricha PJ, Weinshenker BG, Pittock SJ. Intractable nausea and vomiting resulting from antibodies targeting the area postrema aquaporin-4 water channel. Clin Gastroenterol Hepatol, 2013; 11:240-245. PMCID 3581743

http://www.biomedcentral.com/1471-2377/12/11

52

135. Pittock SJ, Mandrekar J, McKeon A, Weinshenker BG, Lennon VA, O’Toole O, Lucchinetti CF, Wingerchuk DM. An open label pilot study of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorders. Lancet Neurol 2013; 12:554-62. PMCID: PMC23623397.

136. Popescu BGF, Pirko I, Lucchinetti CF. Pathology of Multiple Sclerosis: Where Do We Stand? Continuum (Minneap Minn) 2013 Aug; Continuum. 2013 Aug; 19 (4 Multiple Sclerosis):901-21. PMCID PMC 3915566.

137. Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek MLA, Smith CY, McKeon A, Costanzi C, Iorio R, Weinshenker BG, Wingerchuk DM, Shuster EA, Lucchinetti CF, Pittock SJ. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013; 81:1197-1204. PMCID PMC 3795610.

138. Wuthrich C, Popescu BJGh, Gheuens S, Marvi M, Ziman R, Denq SP, Tham M, Norton E,

Parisi JE, Dang X, Lucchinetti CF, and Koralnik IJ. Natalizumab-Associated Progressive Multifocal Leukoencephalopathy in a Patient With Multiple Sclerosis: A Postmortem Study. J Neuropathol Exp Neurol November 2013; 72(11):1043-1051. PMID:24128680. PMC: PMCID4465443.

139. Metz I, Weigand SD, Popescu BF, Stadelmann C, Frischer JM, Parisi JE, Guo Y, Lassmann H, Brück W, Lucchinetti CF. Immunopathologic Heterogeneity Persists in Early Active Multiple Sclerosis Lesions. Ann Neurol 2014 Apr 22: Accepted; 75:728-38. PMCID: PMC 4070313.

*140. Clardy SL, Lucchinetti CF, Krecke KN, Lennon VA, O’Toole O, Weinshenker BG, Boyd CD, Krieger S, McGraw C, Yong G, Pittock SJ. Hydrocephalus in Neuromyelitis Optica. Neurology. 2014 May 20; 82(20):1841-3. Epub 2014 Apr 23. PMCID: PMC 3934000.

141. Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol. 2014 Jan; 24(1):83-97. PMID:24345222. PMCID:3905574.

142. Jiao Y, Fryer MP, Lennon VA, McKeon A, Jenkins SM, Quek AML, Weinshenker BG, Wingerchuk DM, Shuster EA, Lucchinetti CF, Pittock SJ. APQ4-IgG-serostatus and outcome in recurrent longitudinally extensive transverse myelitis. JAMA Neurology 2014; 71:48-54. PMCID: PMC 3934000.

143. Figueroa M, Guo Y, Tselis A, Pittock SJ, Lennon VA, Lucchinetti CF, Lisak RP. Paraneoplastic Neuromyelitis Optica Spectrum Disorder Associated With Metastatic Carcinoid Expressing Aquaporin-4. JAMA Neurology 2014; 71:495-498. PMCID PMC 4076888.

144. Metz I, Weigand SD, Popescu BF, Frischer JM, Parisi JE, Guo Y, Lassmann H, Brück W,

Lucchinetti CF. Pathologic heterogeneity persists in early active multiple sclerosis lesions. Ann Neurol. 2014 May;75(5):728-38. PubMed PMID: 24771535; PubMed Central PMCID: PMC4070313.

145. Howe CL, Kaptzan T, Magana SM, Ayers-Ringler JR, LaFrance-Corey RG, Lucchinetti CF. Neuromyelitis optica IgG stimulates an immunological response in rat astrocyte cultures. Glia 2014 Feb 3. PMCID: PMC24492996.

http://www.ncbi.nlm.nih.gov/pubmed/24771535

53

146. Robinson CA, Adiele RC, Tham M, Lucchinetti CF, Popescu BFGh. Early and widespread injury of astrocytes in the absence of demyelination in acute haemorrhagic leukoencephalitis. Acta Neuropathol Commun. 2014 May 8;2(1):52. PMCID:PMC4035095

147. Clardy SL, Lucchinetti CF, Krecke KN, Lennon VA, O'Toole O, Weinshenker BG, Boyd CD,

Krieger S, McGraw C, Guo Y, Pittock SJ. Hydrocephalus in neuromyelitis optica. Neurology. 2014 May 20; 82(20):1841-3. Epub 2014 Apr 23. PMID:24759842. PMCID:4035709.

*148. Tobin WO, Weinshenker BG, Lucchinetti CF. Longitudinally extensive transverse myelitis. Curr Opin Neurol. 2014 Jun; 27(3):279-89. PMID:24792338.

149. Fryer JP, Lennon VA, Pittock SJ, Jenkins S, Fallier-Becker P, Clardy S, Horta ES, Jedynak E,

Lucchinetti CF, Shuster EA, Weinshenker BG, Wingerchuk DM, McKeon A. AQP4 Autoantibody Assay Performance in Clinical Laboratory Service. Neurol Neuroimmunol Neuroinflamm. 2014 Jun; 1(1):e11. Epub 2014 May 22. PMID:25340055. PMCID:4202686.

150. Brickshawana A, Hinson SR, Romero MF, Lucchinetti CF, Guo Y, Buttmann M, McKeon A, Pittock SJ, Chang MH, Chen AP, Kryzer TJ, Fryer JP, Jenkins SM, Cabre P, Lennon VA. Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol. 2014 Aug; 13(8):795-806. Epub 2014 Jul 06. PMID:25008548. PMCID:4144430.

*151. Guo Y, Lennon VA, Balabanov R, Grouse CK, Milone M, Lassmann H, Parisi JE, Pittock SJ,

Stefoski D, Popescu BFGh, Lucchinetti CF. Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum. JAMA Neurology 2014 March 18; 71:1025-1029. PMC: PMCID24911400.

152. Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, Appendino JP, Lucchinetti CF, Matsumoto JY, Pittock SJ, Sandroni P, Tippmann-Peikert M, Wirrell EC, McKeon A. DPPX potassium channel antibody: Frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. 2014 Nov 11;83(20):1797-803. PubMed PMID: 25320100; PubMed Central PMCID: PMC4240433.

153. Flanagan EP, Weinshenker BG, Krecke KN, Lennon VA, Lucchinetti CF, McKeon A, Wingerchuk DM, Shuster EA, Jiao Y, Horta ES, Pittock SJ. Short Myelitis Lesions in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders. JAMA Neurol. Jan;72(1):81-7, 2015. PMID:25384099. PMCID: PMC4552048.

154. Paz Soldan MM, Novotna M, Abou Zeid N, Kale N, Tutuncu M, Crusan DJ, Atkinson EJ, Siva A, Keegan BM, Pirko I, Pittock SJ, Lucchinetti CF, Weinshenker BG, Rodriguez M, Kantarci OH. Relapses and disability accumulation in progressive multiple sclerosis. Neurology. 2015 Jan 6:84(1):81-8. PubMed PMID: 25398229; PubMed Central PMCID: PMC4336097.

155. Ransohoff R, Hafler D, Lucchinetti CF. Multiple sclerosis: A quiet revolution. Nat Rev Neurol. 2015 Mar:11(3):134-42. PubMed PMID: 25686758. PMCID: PMC4556342.

156. Ransohoff R, Hafler D, Lucchinetti CF. Corrigendum: multiple sclerosis - a quiet revolution. Nat Rev Neurol. 2015 May;11(5):246, 2015. PMID: 25799926

157. Popescu BF, Guo Y, Jentoft ME, Parisi JE, Lennon VA, Pittock SJ, Weinshenker BG,

Wingerchuk DM, Giannini C, Metz I, Brück W, Shuster EA, Carter JL, Boyd CD, Clardy SL, Cohen BA, Lucchinetti CF. Diagnostic Utility of Aquaporin-4 Immunohistochemical Analysis of Active Demyelinating Lesions. Neurology Jan 13; 84(2):148-58, 2015. PMID:25503621. PMCID: PMC4336081.

54

158. Novotna M, Paz Soldán MM, Abou Zeid N, Kale N, Tutuncu M, Crusan DJ, Atkinson EJ, Siva A, Keegan BM, Pirko I, Pittock SJ, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M, Kantarci OH. Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology. 2015 Jul 24. PubMed PMID: 26208962. PMCID: PMC4553030.

159. Pfeifenbring S, Bunyan R, Metz I, Roever C, Huppke P, Gaert NJ, Lucchinetti CF, Brück W. extensive acute axonal damage in pediatric multiple sclerosis lesions. Annals of Neurology, 77:655-667, 2015. PMID: 25612167. PMC:PMCID4523885.

160. Frischer JM, Weigand SD, Guo Y, Kale N, Parisi JE, Pirko I, Mandrekar J, Bramow S, Metz I, Brück W, Lassmann H, and Lucchinetti, CF. Clinical and Pathological Insights into the Dynamic Nature of the MS Plaque. Annals of Neurology 78(5):710-721, November, 2015. MS: 713447. PMID: 26239536. PMCID: PMC4623970.

161. Tobin WO, Popescu BF, Lowe V, Pirko I, Kantarci K, Fields JA, Boeve BF, Lucchinetti CF. Multiple Sclerosis masquerading as Alzheimer type dementia – Clinical, radiological and pathological findings. Multiple Sclerosis Journal April 22(5): 698-704, 2016. PMID: 26447065. PMCID: PMC4808389.

162. Walker-Caulfield ME, Guo Y, Johnson, RK, McCarthy CB, Fitz-Gibbon P, Lucchinetti CF, Howe CL. NFκB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG. Journal of Neuroinflammation 12:185 (Sept. 30), 2015. PMCID: PMC:4590277.

163. Pittock SJ and Lucchinetti CF. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: A decade later. Ann N Y Acad Sci. 2016 Feb;1366(1):20-39. PubMed PMID: 26096370. PMCID: PMC4675706.

164. Pohl D, PhD; Alper G, van Haren K, Kornberg AJ, Lucchinetti CL, Tenembaum S,. Belman AL. Acute Disseminated Encephalomyelitis – Updates on an Inflammatory CNS Syndrome. Neurology Aug 30;87(9 Suppl):S38-45, 2016. PMID: 27572859.

165. Flanagan E, Weinshenker B, St. Sauver J, Majid M, Lennon VA, Lucchinetti CL, McKeon A, Wingerchunk DM, Mandrelar S, Jacobson D, Sagen J, Schmeling JE, Fryer J, Pittock SJ. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Annals of Neurology 79(5):775-78, April 4, 2016. PMID:26239536.

166. Hardy T, Tobin O, and Lucchinetti CL. Exploring the overlap between multiple sclerosis, tumefactive demyelination and Baló’s concentric sclerosis. Multiple Sclerosis Journal 22(8):986-992, July 2016. PMID: 27037180

167. Russi AE, Walker-Caulfield ME, Guo Y, Lucchinetti CF, and Brown MA. Meningeal mast cell-T cell crosstalk regulates T cell. Journal of Autoimmunity Sept;73:100-110, 2016. PMID:27396526.

168. Chuang T-Y, Guo Y, Seki SM, Rosen AM, Johanson DM, Mandel JW, Lucchinetti CF, and Gaultier A. LRP1 expression in microglia is protective during CNS autoimmunity. Acta Neuropathologica Communications Jul 11;4(1):68, 2016. PMID: 27400748 PMCID: PMC4940960

169. Hardy TA, Reddel SW, Barnett MH, Palace J, Lucchinetti CF, Weinshenker BG. Atypical inflammatory demyelinating syndromes of the CNS. Lancet Neurology 15:967-981, August, 2016. PMID: 27478954




55

170. Tillema JM, Weigand S, Mandrekar J, Shu Y, Lucchinetti CF, Pirko I, Port J. In vivo detection of connectivity between cortical and white matter lesions in early MS. Mult Scler 2016, Sept 1, 1352458516671027 Epub 2016, Sept 01.

171. Zalewski N, Lucchinetti CF, Guo, Y, Pittock SJ, Weinshenker BG, Krecke KN, Kaufmann T, Wingerchuk DM., Kumar N, Flanagan E. Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry Dec 2, 2016. PMID:27913626.

172. Wang Y, Cao Y, Mangalam AK, Guo Y, LaFrance-Corey RG, Gamez JD, Atanga PA,. Clarkson BD, Zhang Y, Wang E, Angom RS, Dutta K, Ji B, Pirko I, Lucchinetti CF, and Howe CL. Neuropilin-1 modulates interferon-gamma-stimulated signaling in brain microvascular endothelial cells. Journal of Cell Science Oct 15;129(20):391-3921, 2016. PMID: 27591257 PMCID: PMC5087664.

173. Goodin D, Lubin F, Gareth J, Lucchinetti CL, Miller A, Pelletier D, Racke M, Reder A, Trapp B, Waubant E. Relapses in Multiple Sclerosis: Relationship to Disability. Multiple Sclerosis and Related Disorders 6:10-20, 2016 PMID: 27063617.

174. Tobin WO, Costanzi C, Guo Y, Parisi J, Weigand S, and Lucchinetti C. Clinical- radiological-pathological spectrum of CNS idiopathic inflammatory demyelinating disease in the elderly. Mult Scler Aug;23(9):1204-1213, 2017 PMID:27760861. PMCID:PMC5376381

175. Popescu BF, Frischer JM, Webb SM, Tham M, Adiele RC, Robinson CA, Fitz-Gibbon PD, Weigand SD, Metz I, Nehzati S, George GN, Pickering IJ, Brück W, Hametner S, Lassmann H, Parisi JE, Yong G, Lucchinetti CF. Pathogenic implications of distinct patterns of iron and zinc in chronic MS lesions. Acta Neuropathol. 2017 Jul;134(1):45-64. doi: 10.1007/s00401- 017-1696-8. Epub 2017 Mar 22. PubMed PMID: 28332093; PubMed Central PMCID: PMC5486634.

176. Guo Y, Weigand SD, Popescu BF, Lennon VA, Parisi JE, Pittock SJ, Parks NE, Clardy SL, Howe CL, Lucchinetti CL. Pathological implications of cerebrospinal fluid barrier pathology in neuromyelitis optica. Acta Neuropathologica Feb 9, 2017. PMID:28184993. PMCID: PMC5348570.

177. Tobin W, Guo Y, Krecke K, Parisi J, Lucchinetti C, Pittock S, Mandrekar J, Dubey D, Debruyne J, Keegan BM. Diagnostic Criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain 140(9):2415- 2425, August 24, 2017. PMID: 29050399.

178. Choi J-H, Rosales C, Wallach AI, Belmont HM, Lucchinetti CF, and Minen, MT. Clinical Reasoning: A 50-year-old woman with SLE and a Tumefactive Lesion. Neurology 89:140- 145, September 19, 2017. PMID: 28923891.

179. Parks NE, Flanagan EP, Lucchinetti CF, Wingerchuk DM. NEDA treatment target? No

evident disease activity as an actionable outcome in practice. Journal of the Neurological Sciences Dec 15;383:31-34, 2017. PMID: 29246616.

180. ila J, Guo Y, Gadoth A, Raghunathan A, Parks B, McKeon A, Lucchinetti CF, Lennon VA, Pittock SJ. Purkinje cell cytoplasmic antibody type I (anti-Yo): predictive of gastrointestinal adenocarcinomas in men. J. Neurol Neurosurg Pshychiatry, November 15, 2017. PMID:29142142.

https://www.ncbi.nlm.nih.gov/pubmed/28332093



56

181. Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018 Jan 11;378(2):169-180. Review.PMID:29320652

182. Tillema, J-M, Weigand SD, Dayan M, Shu Y, Kantarci OH, Lucchinetti CF, and Port JD.

Dark Rims: Novel Sequence Enhances Diagnostic Specificity in Multiple Sclerosis. AJNR Am J Neuroradiol. Jun;39(6):1052-1058.2018. PMID: 29700044

183. Stork L, Ellenberger D, Beibarth T, Friede T, Lucchinetti C, Brück W, Metz I. Differences in

the Reponses to Apheresis Therapy of Patients with 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis. JAMA Neurology April 75(4):428-435, 2018. PMID: 29404583 PMCID: PMC5885209.

184. Marin Collazo IV, Howe CL, Lucchinetti CF, Tobin WO. Neuromyelitis Optica and Herpes Simplex Virus 2: A Viral Trigger for Aquaporin-4 Autoimmunity? Neurologist. 2018 May;23(3):92-93. PubMed PMID: 29722742.

185. Lopez-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, Jitprapaikulsan J, Kothapalli N, Tillema JM, Chen J, Weinshenker B, Wingerchuk D, Sagen J, Gadoth A, Lennon VA, Keegan BM, Lucchinetti C, Pittock SJ . Association of MOG-IgG Serostatus with Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. JAMA Neurol. 75(11):1355-1363. 2018. PMID:30014148. PMCID:PMC6248120

186. Jitprapaikulsan J, Chen JJ, Flanagan EP, Tobin WO, Fryer JP, Weinshenker BG, McKeon A, Lennon VA, Leavitt JA, Tillema JM, Lucchinetti C, Keegan BM, Kantarci O, Khanna C, Jenkins SM, Spears GM, Sagan J, Pittock SJ. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. Ophthalmology. 2018 Oct; 125 (10):1628-1637. PMID:29716788

187. Basal E, Zalewski N, Kryzer TJ, Hinson SR, Guo Y, Dubey D, Benarroch EE, Lucchinetti CF, Pittock SJ, Lennon VA, McKeon A. Paraneoplastic neuronal intermediate filament autoimmunity. Neurology. 2018 Oct 30;91(18):e1677-e1689. PMID:30282771.

188. Linnoila J, Guo Y, Gadoth A, Raghunathan A, Parks B, McKeon A, Lucchinetti CF, Lennon VA, Pittock SJ. Purkinje cell cytoplasmic antibody type I (anti-Yo): predictive of gastrointestinal adenocarcinomas in men. J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1116-1117. PMID:29142142

189. Chen JJ, Flanagan EP, Jitprapaikulsan J, Lopez-Chiriboga ASS, Fryer JP, Leavitt JA, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Tobin WO, Keegan BM, Lucchinetti CF, Kantarci OH, McClelland CM, Lee MS, Bennett JL, Pelak VS, Chen Y, VanStavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Brazis PW, Sagen J, Pittock SJ. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. Am J Ophthalmol. 2018 Nov;195:8-15. PMID:30055153.

190. Parks NE, Pittock SJ, Mandrekar J, Kantarci OH, Lucchinetti CF, Weinshenker BG, Keegan BM, Tobin WO, Tillema JM, Toledano M, Flanagan EP. Population-based study of "no evident disease activity" in MS. Neurol Neuroimmunol Neuroinflamm. 2018 Nov 16;5(6):e495. 2018 Nov. PMID:30211251.




http://quarterly.mayo.edu/directory/person/person.htm?per_id=15927547














https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248120/























































57

191. Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, Weinshenker BG, Shosha E, Lucchinetti CF, Fryer JP, Lopez-Chiriboga AS, Chen JC, Jitprapaikulsan J, McKeon A, Gadoth A, Keegan BM, Tillema JM, Naddaf E, Patterson MC, Messacar K, Tyler KL, Flanagan EP. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurol. 2018 Dec 21. PMID: 30575890.

192. Zekeridou A, Kryzer T, Guo Y, Hassan A, Lennon V, Lucchinetti CF, Pittock S, McKeon A.

Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity. Neurology, August 20, 2019; 93(8)e815-e822. PMID: 31315972.

193. Eckel-Passow JE, Decker PA, Kosel ML, Kollmeyer TM, Molinaro AM, Rice T, Caron AA, Drucker KL, Praska CE, Pekmezci M, Hansen HM, McCoy LS, Bracci PM, Erickson BJ, Lucchinetti CF, Wiemels JL, Wiencke JK, Bondy ML, Melin B, Burns TC, Giannini C, Lachance DH, Wrensch MR, Jenkins RB. Using germline variants to estimate glioma and subtype risks. Neuro Oncol. 2019 Mar 18; 21 (4):451-461. PMID: 30624711 PMCID: PMC6422428.

194. Ruegsegger GN, Vanderboom P, Dasari S, Klaus K, Kabiraj P, Lucchinetti CF, Nair KS. Exercise and metformin counteract altered mitochondrial function in the insulin resistant brain. Journal of Clinical 2019 Sep 19;4(18). PMID:31534057.

195. Flanagan EP, Pittock S J, Krecke K N, Morris, PP. Sechi E, Zalewski NL, Weinshenker BG, Eslam S, Lucchinetti CF, Fryer JP, Lopez Chiriboga AS, Chen JJ, Jitprapaikulsan J, McKeon A, Keegan B M, Tillema, J-M, Naddaf E, Patterson M C, Messacar K. Myelitis Associated with Myelin Oligodendrocyte Glycoprotein Autoantibody; Clinical characteristics, MRI clues and discriminators from other etiologies. JAMA Neurol. 2019; 76(3):301-309.

196. Kalinowska-Lyszczarz A. Fereidan Esfahani, Mahboobeh FE; Guo Y, Lucchinetti CF, Tobin W. Pathological findings in Central Nervous System Demyelination associated with Infliximab. Multiple Sclerosis Journal. Accepted for Publication October 2019

197. Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Lopez Chiriboga AS, Fryer JP, Weinshenker BJ, McKeon A, Tillema J-M, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, VanStavern G, Adesin O-O, Eggenberger ER, Acierno MD, Wingerchuk DM, Pittock SJ. Steroid-Sparing Immunosuppression for relapsing Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Associated Disorder. Neurology, Accepted.

198. Hoftberger R, Guo Y, Flanagan E, Lopez-Chiriboga S, Weigand S, Endmayr V, HOchmeister S, Joldic D, PIttocj S, Mendelt JM, Gorman M, Lassmans H, Lucchinetti CF. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Accepted, Acta Neurolopathologica, January, 2020.

199. Höftberger R*, Guo Y*, Lopez-Chiriboga S, Flanagan EP, Weigand SD, Pittock SJ, Gorman M, Lassmann H, and Lucchinetti CF. *Contributed equally. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Submitted.

200. Kalinowska-Lyszczarz A, Tillema J-M, Tobin WO, Guo Y, Fitz-Gibbon PD, Weigand SD, Giraldo-Chica M, Port JD, Lucchinetti CF. Long-term follow-up on clinical, radiographic and cognitive outcomes in pathologically confirmed Multiple Sclerosis. Submitted, July 2019 to Neurology.




58

201. Tham M, Frischer JM, Weigand SD, Fitz-Gibbon PD, Webb SM, Guo Y, Adiele RC, Robinson CA, Brück W, Lassmann H, Furber KL, Pushie MJ, Parisi JE, Lucchinetti CF*, Popescu BF. Iron heterogeneity in early active multiple sclerosis lesions. * Co-corresponding author Submitted Brain 2019.

202. Wilkins J, Gakh O, Parijat Kabiraj P, McCarthy CB, Tobin WO, Howe CL, Lucchinetti CL. Signatures of cell stress and altered bioenergetics in skin fibroblasts from patients with multiple sclerosis. Molecular Neurodegeneration. Submitted February 2020.

203. Lopez-Chiriboga S, Sechi E, Buciuc M, Pittock SJ, Chen JJ. Weinshenker BG, Wingerchuk D, Dubey D, Marin-Collazo V, Eggenberger E, Kunchok A, Tillema J-M, Lucchinetti CF, Flanagan E. Long-term Outcomes in Myelin Oligodendrocyte Glycoprotein-IgG. (MOG-IgG)-Associated Disorders. Annals of Neurology, Submitted February 2020.

Books, Chapter/Reports

1. Lucchinetti CF, Lassmann H. Multiple Sclerosis Neuropathology. In, Glial Cell Development: Basic Principles and Clinical Relevance; Eds K R Jessen and W D Richardson; Bios Scientific Publishers.

2. Litchy W, Lucchinetti CF, Taylor F. Intravenous Immune Gamma Globulin (IVIG for Treatment of Neurological Conditions. Report for Technology Assessment Committee with Institute for Clinical Systems Integration. 1997.

3. Editor: Robert Brown. Neurology Section. Co-authors: Boeve B, Britton J, Dodick D, Lucchinetti CF, Suarez G. American College of Physicians Medical Knowledge Self- Assessment Program. January 2001.

4. Lucchinetti CF, Lassman H. Immunopathology of Multiple Sclerosis. IN: Neuroinflammation: Mechanisms and Management (2nd edition). Eds: P Wood. Totowa, NJ: Humana Press, 2003. pp. 359-378.

5. Lucchinetti CF, Brück W, Lassman H. Pathology and pathogenesis of multiple sclerosis. IN: Multiple Sclerosis 2. Eds. W. I. McDonald and J.H. Noseworthy. Blue Books of Practical Neurology, vol. 27. Boston: Butterworth-Heinemann, 2003. pp. 93-113.

6. Lucchinetti CF, Weinshenker BG. Fulminant White Matter Disease. IN: Tough Calls in

Acute Neurology. Editors: Rabinstein A, Wijdicks E. New York: Elsevier/Butterworth- Heinemann; 2004. p. 293-307.

*7. Morales, Yazmin BA; Parisi, Joseph E, MD; Lucchinetti, Claudia F, MD. The Pathology of Multiple Sclerosis: Evidence for Heterogeneity. Advances In Neurology: 2006; 98:27- 45.

8. Lucchinetti, CF. The Pathology of Multiple Sclerosis. What May it Tell Us? In: Cook SD, editor. Handbook of multiple sclerosis. 4th Edition. Vol. 80. New York: Taylor & Francis; 2006. (Neurological Disease and Therapy.). P. 113-51.

*9. Pittock, S, and Lucchinetti, CF. Heterogeneity in MS. Clinical Implications. Neurologist. 2006.

10. Lucchinetti, CF. Multiple Sclerosis Pathology during Early and Late Disease Phases. IN: Immune Regulation and Immunotherapy in Autoimmune Disease. Editor: Zhang, J. New York: Springer. 2007. pp. 214-264.

11. Lucchinetti CF. Pathological heterogeneity of idiopathic central nervous system

59

inflammatory demyelinating disorders. IN: Advances in Multiple Sclerosis and Demyelinating Disease. Ed. Rodriguez M. 1 ed. Current Topics in Microbiology & Immunology. 318:19-43.

Berlin-Heidelberg: Springer-Verlag; 2008.

*12. Young NP, Weinshenker BG, Lucchinetti CF. Acute Disseminated Encephalomyelitis: Current Understanding and Controversies. Semin Neurology 28(1): 84-94. Guest Editor: Lucchinetti CF. New York: Thieme Medical Publishers, 2008.

13. Lucchinetti CF. Multiple sclerosis and the spectrum of CNS inflammatory demyelinating

diseases. Semin Neurology 28(1):3-6. Guest Editor; Lucchinetti CF. New York: Thieme Medical Publishers, 2008.

*14. Hu W, Lucchinetti CF. The Pathological Spectrum of CNS Inflammatory Demyelinating Diseases. Semin Immunopathol. 2009 Nov; 31:439-453. Epub 2009 Sep 25.

*15. Roemer SF, Lucchinetti CF. Immune effector heterogeneity in multiple sclerosis and related CNS inflammatory demyelinating disorders. In: Kilpatrick T; Ransohoff RM; Wesselingh S editor. Inflammatory diseases of the central nervous system. Cambridge; New York: Cambridge University Press; 2010. (Cambridge Medicine.). p. 47-73.

*16. Young NP, Weinshenker BG, Lucchinetti CF. Acute disseminated encephalomyelitis. In: Lucchinetti CF; Hohlfeld R editor. Multiple sclerosis 3. 1st Edition. Philadelphia: Saunders/Elsevier; 2010. (Blue Books of Neurology.). p. 219-236.

17. Lucchinetti CF, Hohlfeld R. Multiple sclerosis 3. 1st Edition. Volume 34. Philadelphia: Saunders/Elsevier; 2010. (Blue Books of Neurology)

18. Lucchinetti CF. Taking a Microscopic Look in MS. Primer of Multiple Sclerosis. IN: Primer on Multiple Sclerosis. Ed. Giesser, B. New York: Oxford University Press, 2011, pp. 61-80.

*19. Bunyan RF, Lucchinetti CF. Tumefactive multiple sclerosis. In: Reder AT, editor. MedLink Neurology. San Diego: MedLink Corporation,October 2010, Available at www.medlink.com. Originally released June 25, 2010; expires June 25, 2013.

*20. Popescu BFGh, Lucchinetti CF. Pathology of Demyelinating Diseases. IN: Annual Review of Pathology: Mechanisms of Diseases, 2012; 7:185-217.

21. Lucchinetti CF, Gong Y, Popescu BF, Fujihara K, Itoyama Y, Misu T. The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica. NMO Symposium, Brain Pathol 2014; 24:83-97. PMCID: PMC3905574.

*22. Tobin WO, Weinshenker BG, Lucchinetti CF. Longitudinally Extensive Transverse Myelitis. Curr Op Neurol 2014; 27:279-289.

23. Guo Y and Lucchinetti CF. Taking a Microscopic Look in Multiple Sclerosis. IN: Primer on Multiple Sclerosis. Ed. Giesser, B. New York: Oxford University Press.

23. Lucchinetti CF, Popesco BF. Neuropathology of Multiple Sclerosis. IN: Multiple Sclerosis: A Mechanistic View 1st Edition, 2015, in press.

24. Lucchinetti CF, Pittock SJ, Popescu BF. Immunopathology: Autoimmune glial diseases and Differentiation from Multiple Sclerosis. IN: Handbook of Clinical Neurology “Autoimmune Neurology.” 133:95-106, 2016.

http://www.thieme-connect.com/ejournals/abstract/sin/doi/10.1055/s-2007-1019130

http://www.thieme-connect.com/ejournals/abstract/sin/doi/10.1055/s-2007-1019130

http://www.medlink.com/

60

25. Lucchinetti CF, Popescu BF. Multiple Sclerosis: Pathology. IN: Neurobiology of Disease, 2nd Edition, 2015.

Editorials/Letter

1. Rodriguez M, Lucchinetti CF. Is apoptotic death of the oligodendrocyte a critical event in the pathogenesis of multiple sclerosis? (Editorial) Neurology 1999; 53:1615-1616.

*2. Pittock SJ, Weinshenker BW, Lucchinetti CF. Bright Red Nuclei. (Editorial) Neurology 2004; 62:619.

*3. Pittock SJ, Weinshenker BW, Lucchinetti CF. Bright Red Nuclei – Reply. Neurology 2004; 63:1543.

4. Lucchinetti CF, Brück W, Lassmann H. Evidence for Pathogenic Heterogeneity in Multiple Sclerosis. (Letter) Ann Neurol 2004; 56:308.

5. Pittock SJ, Weinshenker BG, Noseworthy JN, Lucchinetti CF, Keegan M, Wingerchuk DM, Carter J, Shuster E, Rodriguez, M. Not every patient with multiple sclerosis should be treated at time of diagnosis. (Editorial) Arch Neurol 2006; 63:611-614.

6. Lassmann H, Lucchinetti CF. Cortical demyelination in CNS inflammatory

demyelinating diseases. (Editorial) Neurology; 2008 Jan 29;70(5):332-3. PubMed PMID: 18227414.

7. Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS, Azzarelli B, Kolar OJ, Atkins HL, Bruck WG. Autologous hematopoietic stem cell transplantation: the glass seems to be half full for aggressive, early forms of MS and half empty for advanced MS - art. no. e90. Brain 2008 Feb; 131(Part 2):E90. (Letter).

*8. Kale N, Pittock SJ, Lennon VA, Thomsen K, Roemer S, McKeon A, Lucchinetti CF. Humoral pattern II multiple sclerosis pathology not associated with neuromyelitis Optica IgG. Arch Neurol 2009 Oct; 66(10):1298-9. DOI:10.1001/archneurol.2009.199. (Letter)

9. Lennon, VA, Hinson SR, Romero MF, Lucchinetti CF. Response to Rossi et al.: Immunohistopathological findings in neuromyelitis optica concur with immunobiological observations in vitro. PNAS 2012; 109: E1512. PMCID: PMC3386078

10. Fujihara K, Lucchinetti C. Mini-Symposium: Neuromyelitis Optica (NMO), Part 1.

New Insights, Promises and Challenges. Brain Pathology 2013; 23:645-646. 11. Fox, RJ. Tissue Markers for Acute Multiple Sclerosis Treatment Response—A Step

Toward Personalized Medicine. JAMA Neurology, February 2018.

Abstracts (not complete list)

1. Lucchinetti CF, Kerns J. A comparison of cryoprobe and crush lesions in the rat sciatic nerve. (Poster) National Neuroscience Meeting, Phoenix, AZ, 1989.

2. Lucchinetti CF, Kerns J. Electrical field effects on crushed nerve regeneration. (Poster) National Neuroscience Meeting, Phoenix, AZ, 1989.

61

3. Lucchinetti CF, Kimmel DW, Lennon VA. Clinical, oncological, and serological profiles of patients seropositive for type 1 anti-neuronal nuclear antibody (anna-1, a.k.a. 'anti-Hu'). (Poster -Abstract no. 129p) American Academy of Neurology, Washington DC, April 1994. Neurology 1994; 44(Suppl):A156.

4. Lucchinetti CF, Camilleri M, Lennon VA. Gastrointestinal dysmotility spectrum in patients seropositive for paraneoplastic type 1 anti-neuronal nuclear autoantibodies. (Poster) Fifth International Symposium on the Autonomic Nervous System, Rochester, MN, Clin Autonom Res 4:206, 1994.

5. Lucchinetti CF, Kimmel DW, Pavelko K, Rodriguez M,. Development of an animal model

for multi-focal inflammatory demyelination induced by 5-fluorouracil and levamisole. (Poster - Abstract no. 1070P). American Academy of Neurology, Seattle, WA, April 1995. Neurology 1995; 45 (Suppl):A462.

6. Lucchinetti CF, Lennon VA. Neurologic and oncologic correlations in patients seropositive for type 2 antineuronal nuclear autoantibodies. (Poster - Abstract p01.049) American Academy of Neurology, San Francisco, CA , April 1996. Neurology 1996; 46(Suppl):1049.

7. Lucchinetti CF. Oligodendrocyte Loss and Preservation in Early MS. (Poster) Fourth Altschul Symposium, Saskatoon, SK, June 1996.

8. Brück WB, Lucchinetti CF, Lassmann H. Bcl-2 Expression in Oligodendrocytes from Multiple Sclerosis Lesions. (Poster) European Charcot Foundation, Vienna, Austria, July 1996.

9. Lucchinetti CF. Clinical trials on MS patients with fixed neurological deficits. Symposium on Remyelination in Multiple Sclerosis. (Platform) European Charcot Foundation, Vienna, Austria, July 1996.

10. Lucchinetti C, Rodriguez M, Brück W, Scheithauer BW, Parisi J, Lassmann H.

Oligodendrocyte loss and preservation in early multiple sclerosis. (Poster) American Neurological Association, Miami, FL, October 1996. Ann Neurol 1996; 40:522.

11. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Loss of myelin-associated glycoprotein in active multiple sclerosis lesions associated with oligodendrocyte apoptosis. (Platform) Frontiers of Myelin Biology and Demyelinating Disease Meeting. Mystic, CT, July 1997.

12. Lucchinetti CF. Monoclonal antibodies and their effects on experimental remyelination. (Platform) European Charcot Foundation, Madrid, Spain, October 1997.

13. Lucchinetti CF, Brück W, Scheithauer B. Parisi J, Rodriguez M, Lassmann H. Immunopathology of multiple sclerosis. (Platform) American Association of Neuropathologists, Minneapolis, MN, 1998.

14. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Patterns of multiple sclerosis

immunopathology. J Neurochem 1998; 70(Suppl 1):S19.

15. Lucchinetti CF, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Patterns of multiple sclerosis immunopathology. JNEN 1998; 57:489.

62

16. Weinshenker, BG, O'Brien, PC, Petterson, TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens, LN, Rodriguez M. Plasma exchange reverses severe neurological disability in corticosteroid-refractory attacks of idiopathic inflammatory demyelinating disease of the CNS. 4th Annual Meeting of American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Basel, Switzerland, 1999 September.

17. Boeve B, Parisi J, Dickson D, Maraganore D, Ahlskog JE, Graff-Radford N, Caselli R,

Lehman M, Duffy J, Muenter M, Kokmen E, Aksamit A, Lucchinetti C, Petersen R. Demographic and clinical findings in 20 Cases of pathologically diagnosed corticobasal degeneration. (Abstract P1058). Movement Disorder Society Sixth International Congress of Parkinson’s Disease and Movement Disorders, Barcelona, Spain, June 2000. Mov Disord 2000; 15(Suppl 3):228.

18. Geda Y, Boeve B, Parisi J, Dickson D, Maraganore D, Ahlskog JE, Graff-Radford N,

Caselli R, Muenter M, Kokmen E, Aksamit A, Lucchinetti C, Petersen R. Neuropsychiatric features in 20 cases of pathologically confirmed corticobasal degeneration. (Abstract P1062). Movement Disorder Society Sixth International Congress of Parkinson’s Disease and Movement Disorders, Barcelona, Spain, June 2000. Mov Disord 2000; 15(Suppl 3):229.

19. Hauser M, Mullan B, Boeve B, Maraganore D, Ahlskog JE, Parisi J, Dickson D, Kokmen K,

Aksamit A, Lucchinetti C, Petersen R. SPECT findings in clinically-and/or pathologically diagnosed corticobasal degeneration. (Abstract P1035). Movement Disorder Society Sixth International Congress of Parkinson’s Disease and Movement Disorders, Barcelona, Spain, June 2000. Mov Disord 2000; 15(Suppl 3):221.

20. Westmoreland B, Boeve B, Parisi J, Dickson D, Maraganore D, Ahlskog JE, Graff-Radford N, Kokmen E, Aksamit A, Lucchinetti C, Petersen R. Electroencephalographic findings in clinically and/or pathologically diagnosed corticobasal degeneration. (Abstract P1063). Movement Disorder Society Sixth International Congress of Parkinson’s Disease and Movement Disorders, Barcelona, Spain, June 2000. Mov Disord 2000; 15(Suppl 3):229.

21. Lucchinetti CF, Mandler R, Weinshenker B, Wingerchuck D, Parisi J, Lassmann H. Humoral Mechanisms in the Pathogenesis of Neuromyelitis Optica. (Platform-Highlighted in Scientific Session) American Academy of Neurology, San Diego, CA, May 2000.

22. Lucchinetti CF. MS Lesion Project – Examining MS lesions to see why people experience

MS differently. (Platform) National MS Society Minnesota Chapter Research Symposium, Rochester, MN, April 2001.

23. Boeve B, Castillo P, Caselli R, Vernino S, Lucchinetti C, Swanson J, Noseworthy J, Aksamit A, Flemming K, Hunder G, Fatourechi V, Mokri B, Lennon V. Steroid-responsive encephalopathy associated with thyroid autoimmunity: outcome with immunomodulatory therapy. 17th World Congress of Neurology, London, UK, June 2001. J Neurol Sci 2001; 70(6):S441.

24. Castillo P, Boeve B, Caselli R, Vernino S, Lucchinetti C, Swanson J, Noseworthy J, Aksamit A, Fleming K, Hunder G, Fatourechi V, Mokri B, Lennon V. Steroid-responsive encephalopathy associated with thyroid autoimmunity: clinical and laboratory findings. 17th World Congress of Neurology, London, UK, June 2001. J Neurol Sci 2001; 187(Suppl 1):S492.

63

*25. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2 (ANNA-2, or "anti Ri"): Neurological, oncological and serological accompaniments and frequency. American Academy of Neurology, Philadelphia, PA, May 2001, Neurology 2001; 56 (Suppl. 3):A41.

26. Lucchinetti CF. Heterogeneity of multiple sclerosis pathogenesis: Implication for diagnosisand therapy. (Platform) American Academy of Neurology, Philadelphia, PA, May 2001.

27. Scarisbrick IA, Lucchinetti CF, Rodriguez M. A trypsin-like serine protease abundantly expressed in the adult central nervous system: changes in multiple sclerosis lesions. (Abstract). J Neuropathol Exp Neurol. 60:506, 2001.

*28. Keegan M, Berger T, Lucchinetti C, Reindl M, Rodriguez M, Noseworthy J, Weinshenker

Antibodies to myelin proteins in patients with severe attacks of demyelinating disease who undergo therapeutic plasma exchange. American Academy of Neurology, Philadelphia, PA, May 2001, Neurology 2001; 56(8 Suppl 3):A366.

29. Lucchinetti CF. Differential diagnosis of MS: Conditions that mimic MS. (Platform) Minnesota Society of Neurological Sciences Fall Conference and Annual Meeting, Bloomington, MN, November 2001.

30. Castillo PR, Boeve BF, Caselli RJ, Vernino SA, Lucchinetti C, Swanson JW, Noseworthy JH, Askamit AJ, Flemming KD, Hunder GG, Fatourechi V, Mokri B, Lennon VA. Steroid responsive encephalopathy associated with thyroid autoimmunity: clinical and laboratory findings. (Poster) American Academy of Neurology, Denver, CO, April 2002, Neurology 2002; 58(Suppl):A248.

31. Wingerchuk DM, Benarroch E, O'Brien PC, Keegan BM, Lucchinetti CF, Noseworthy JH,

Weinshenker BG, Rodriguez M. Aspirin for multiple sclerosis-related fatigue: results of a double-blind placebo-controlled study. (Poster) American Academy of Neurology, Denver, CO, April 2002, Neurology 2002; 58(Suppl 3):A492.

32. Weinshenker B, Wingerchuk DM, Lucchinetti CF, Lennon VA. A marker autoantibody

discriminates neuromyelitis optica from multiple sclerosis. (Platform) American Academy of Neurology, Honolulu, HI, April 2003.

33. Lennon VA, Lucchinetti CF, Weinshenker BG. Identification of a marker autoantibody of neuromyelitis optica. (Platform) American Academy of Neurology, Honolulu, HI, April 2003.

34. Lucchinetti CF, Wegner C, Altintas A, Menk S, Lassmann H, Bitsch A, Brück W. The

histopathological correlates of ring-enhancement in multiple sclerosis lesions. (Poster) American Neurological Association, San Franciso, CA, October 2003. Ann Neurol 2003; 54:S37-38.

35. Lucchinetti CF, Wegner C, Altintas A, Menk S, Lassmann H, Bitsch A, Brück W. MRI correlates of heterogeneous multiple sclerosis pathology. (Poster) American Neurological Association, San Francisco, CA, October 2003. Ann Neurol 2003; 54:S37.

36. Pittock SJ, McClelland R, Achenbach SJ, Bitsch A, Brück W, Lassmann H, Rodriguez M,

Parisi J, Scheithauer BW, Lucchinetti CF. The Clinical Course of Biopsy-Proven Demyelinating Disease and Comparison with a Population-based MS Prevalence Cohort (Platform). ACTRIMS: American Committee for Treatment and Research in MS, San Francisco, CA, October 2003.

64

37. Pittock SJ, Parisi JE, Keegan M, Lucchinetti CF, Hunter SF, Lennon VA. Jaw Opening Dystonia and Laryngospasm Associated with Paraneoplastic Antineuronal Nuclear Autoantibody-Type 2. Ann Neurol 2003; 54:S70.

38. Weinshenker BW, Ziemer PA, Hebrink DD, Atkinson EJ, Achenbach SJ, De Andrade M,

Mahad DJ, Ransohoff RM, Lucchinetti CF. Δ32CCRS Mutation and the Course and Histopathology of MS. ACTRIMS: American Committee for Treatment and Research in MS, San Francisco, CA, October 2003. Mult Scler 2004; 10 (1).

39. Mahad DJ, Trebst C, Kivisakk P, Tucky B, Wujek J, Trapp BD, Lucchinetti CF, Lassmann H, Ransohoff RM. Distinct profiles of chemokine receptor expression in pattern II and III multiple sclerosis lesions. J Neurol Neurosurg Psych 2004; 75:517.

40. Pittock S, Stephan C, Lucchinetti CF, Parisi JE, Lennon VA. Amphiphysin Autoantibody: Neurological, Oncological, Pathological, and Serological Accompaniments in 60 Patients Platform. American Academy of Neurology, San Francisco, April 2004. Neurology 2004; 62:A263-264.

41. Keegan BM, Konig F, Bitsch A, Brück W, Lassmann H, Panitch H, Rodriguez M,

Weinshenker BW, McClelland R, Parisi J, Lucchinetti CF. Pathological subtype of MS predicts treatment response to therapeutic plasma exchange. (Platform) American Academy of Neurology, San Francisco, CA, April 2004. Neurology 2004; 62:A259-260.

42. Aboul-Enein F, Hoftberger R, Bruck W, Lucchinetti C, Rodriguez M, Schmidbauer M, Jellinger K, Lassmann H. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions (Abstract P248). Mult Scler 2004 Sep; 10(Suppl 2):S153-4.

43. Altintas A, Bieber A, Rodriguez M, Ziemer P, Lucchinetti C. Preservation of

oligodendrocytes in Theiler's murine encephalomyelitis virus (Tmev) induced demyelination (Abstract P415). Mult Scler 2004 Sep; 10(Suppl 2):S197.

*45. Kantarci OH, Ziemer P, Konig F, Bruck W, Lassmann H, Lucchinetti CF. Gender

differences in immunopathological patterns of multiple sclerosis. (Poster -Abstract P250). ECTRIMS, Vienna, Austria, October 2004. Mult Scler 2004 Sep; 10(Suppl 2):S154.

46. Kutzelnigg A, Rauschka H, Stadelmann C, Schmidbauer M, Bruck W, Lucchinetti C,

Lassmann H. Pathological substrate of disease progression in multiple sclerosis (Abstract 624). J Neuroimmunol 2004 Sep; 154(1-2):189.

*47. Morales Y, Kantarci OH, Konig F, Bruck W, Achenbach SJ, McClelland RL, Moore SB, Lassmann H, Lucchinetti CF. An association study of HLA class II alleles and immunopathological patterns in multiple sclerosis. (Platform - Abstract P441). ECTRIMS, Vienna, Austria, October 2004. Mult Scler 2004 Sep; 10(Suppl 2):S203.

*48. Pittock SJ, Berger T, Bruck W, Konig F, Morales Y, Lassmann H, Achenbach S, McClelland R, Reindl M, Moore B, Keegan BM, Lucchinetti, CF. Anti Myelin Antibodies: Frequency, Stability, and Clinicopathologic Correlations. (Platform) ACTRIMS: American Committee for Treatment and Research in MS, Toronto, ON, October 2004.

49. Lucchinetti, CF. Update on the International MS Lesion Project. (Platform ) ACTRIMS American Committee for Treatment and Research in MS, Toronto, ON, October 2004. Mult Scler 2005; 11:99-100.

65

*50. Pittock SJ, Wingerchuk DM, Krecke K, Lennon VA, Lucchinetti CF, Weinshenker BG.

Brain abnormalities in patients with neuromyelitis optica (NMO) (Platform - Abstract P01.036). American Academy of Neurology, Miami Beach, FL, April 2005, Neurology 2005; 64(6 Suppl 1):A39.

51. Wingerchuk DM, Pittock SJ, Lennon VA, Lucchinetti CF, Weinshenker BG. Neuromyelitis

optica diagnostic criteria revisited: validation and incorporation of the NMO-IgG serum autoantibody (Platform - Abstract P01.033). American Academy of Neurology, Miami Beach, FL, April 2005, Neurology 2005; 64(6 Suppl 1):A38.

*52. Roemer SE; Scheithauer BW, Erickson BJ, Lucchinetti CF. The concurrence of

inflammatory demyelination and anaplastic astrocytoma in a single brain biopsy. JNEN 2005; 64:435.

53. Kutzelnigg AE, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, Schmidbauer M, Parisi J, Lassmann H. Brain damage outside demyelinated white matter plaques in multiple sclerosis (Abstract 23). ACTRIMS: American Committee for Treatment and Research in MS, Thessaloniki, Greece, October 2005. Mult Scler 2005 Sep; 11(Suppl 1):S5. (Abstract)

54. Patrikios P, Kutzelnigg A, Faber-Rod J, Lucchinetti C, Bruck W, Lassmann H. Shadow

plaques and remyelination in multiple sclerosis (Abstract P673). ACTRIMS: American

Committee for Treatment and Research in MS, Thessaloniki, Greece, October 2005. Mult Scler 2005 Sep; 11(Suppl 1):S179.

*55. Pittock SJ, Wingerchuk DM, Krecke K, Lennon VA, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica (optic-spinal MS). (Abstract P106) ACTRIMS: American Committee for Treatment and Research in MS, Thessaloniki, Greece, October 2005. Mult Scler 2005 Sep; 11(Suppl 1):S23.

56. Pomeroy IM, Esiri MM, Palace J, Roemer SF, Lucchinetti CF. A case of MS, ADEM, NMO

or all three? (Abstract P96). ACTRIMS: American Committee for Treatment and Research in MS, Thessaloniki, Greece, October 2005. Mult Scler 2005 Sep; 11(Suppl 1):S20.

57. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, Lennon

VA. NMO-IgG predicts relapse in patients with longitudinally extensive transverse myelitis (Abstract P500). ACTRIMS: American Committee for Treatment and Research in MS, Thessaloniki, Greece, October 2005. Mult Scler 2005 Sep; 11(Suppl 1):S130.

*58. Keegan M, Giannini C, Parisi JE, Lucchinetti CF, Boeve BF, Josephs KA. Adult onset, sporadic leukodystrophy with neuroaxonal spheroids mimicking cerebral MS (Abstract M- 16). American Neurological Association, Chicago, IL, October 2006. Ann Neurol 2006; 60(Suppl 10):S39.

*59. Pittock SJ, Weinshenker BG, Wingerchuk DM, Lucchinetti CF, Lennon VA. Autoimmune neurological accompaniments of neuromyelitis optica (NMO) (Abstract M-24). American Neurological Association, Chicago, IL, October 2006. Ann Neurol 2006; 60(Suppl 10):S41.

60. Porter Umphrey A, Giannini C, Kaufmann TJ, Lucchinetti CF, Atkinson JLD, O'Neill BP. Primary central nervous system lymphoma (PCNSL) can be diagnosed with concurrent corticosteroid (CS) use. A pilot study to determine effect of CS on the diagnosis of PCNSL (Abstract M-37). American Neurological Association, Chicago, IL, October 2006. Ann Neurol 2006; 60(Suppl 10):S44.

66

*61. Erickson BJ, Bryant SC, Mandrekar J, Bruck W, Lassmann H, Parisi JE, Morales Y, Roemer S, Lucchinetti C. MRI intensities correlate with immunopathologic patterns in multiple sclerosis (Abstract S22.002). American Academy of Neurology, San Francisco, CA, April 2006. Neurology 2006; 66(5 Suppl 2):A183.

*62. Gavrilova RH, Erickson B, Altintas A, Bamlet WE, Mandrekar J, Achenbach S, Parisi JE,

Scheithauer B, Lucchinetti CF. The radiographic spectrum of biopsy proven inflammatory demyelinating disease (Abstract S22.006). American Academy of Neurology, San Francisco, CA, April 2006. Neurology 2006; 66(5 Suppl 2):A184.

64. Morales Y, Achenbach SJ, Mandrekar JN, Lassmann H, Bruck W, Parisi JE, Lucchinetti

B. Association of T-lymphocyte infiltrate with demyelinating activity, tissue injury and repair, and immunopathological patterns in early multiple sclerosis (MS) lesions (Abstract P06.178). American Academy of Neurology, San Francisco, CA, April 2006. Neurology 2006; 66(5 Suppl 2):A374.

*65. Pittock SJ, Lennon VA, Wingerchuk DM, Homburger HA, Lucchinetti CF, Weinshenker BG. The prevalance of non-organ-specific autoantibodies and NMO-IgG in neuromyelitis optica (NMO) and related disorders. (Abstract P05.196) American Academy of Neurology, San Francisco, CA, April 2006. Neurology 2006; 66(5 Suppl 2):A307.

*66. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corby JR, Lennon VA. MRI brain lesions characteristic of neuromyelitis optica (NMO) colocalize with sites of high aquaporin protein concentrations (Abstract S22.004). American Academy of Neurology, San Francisco, CA, April 2006. Neurology 2006; 66(5 Suppl 2):A183.

*67. Roemer S, Stadelmann C, Bruck W, Morales Y, Parisi JE, Lucchinetti CF. Cortical demyelination is present in early multiple sclerosis (Abstract P02.080). American Academy of Neurology, San Francisco, CA, April 2006. Neurology 2006; 66(5 Suppl 2):A93-4.

68. Wingerchuk D, Pittock S, Lennon V, Lucchinetti C, Weinshenker B. Secondary clinical progression is rare in relapsing neuromyelitis optica (Abstract S52.002). American Academy of Neurology, San Francisco, CA, April 2006. Neurology 2006; 66(5 Suppl 2):A380.

69. Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman M, Azzarelli B, Kolar OJ, Atkins HL, Bruck W. Multiple sclerosis pathology after autologous stem cell transplantation: ongoing demyelination and neurodegeneration despite suppressed inflammation. Mult Scler 2006 Sep; 12(Suppl 1):S9.

70. Jacobs D, Roemer S, Weinshenker B, Pittock S, Wingerchuk D, Lennon V, Lucchinetti CF. The pathology of brain involvement in neuromyelitis optica spectrum disorder. Mult Scler 2006 Sep; 12; S155.

71. Wingerchuk D, Pittock S, Lennon V, Lucchinetti CF, Weinshenker B. The rate of

conversion to a secondary progressive course is lower in neuromyelitis optica than multiple sclerosis. Mult Scler 2006 Sep; 12: S155.

72. Weinshenker B, Pittock S, de Seze J, Vermersch P, Wingerchuk D, Zephir H, Homburger

H, Lucchinetti CF, Lennon V. The relationship between neuromyelitis optica and systemic autoimmune disease. Mult Scler 2006 Sep; 12(Suppl 1):S16.

*73. Roemer SF, Mateen FJ, Parisi JE, Scheithauer BW, Lucchinetti CF. Acute mental status changes at initial presentation of multiple sclerosis (MS). Brain Path 2006; 16: S68.

67

*74. Roemer SF, Kantarci OH, Erickson BJ, Parisi JE, Lucchinetti CF. Symptomatic cortical demyelination in early MS. Brain Path 2006; 16:S67.

75. Parisi JE, Lucchinetti CF, Aksamit AJ, Campeau NG, Wald JT. Primary angiitis of the central nervous system (PACNS) with predominant white matter damage. Brain Path 2006; 16:S91.

76. Kantarci OH, Daugherty WP, Rodriguez FJ, Shaw EG, Parisi JE, Atkinson JL, Lucchinetti CF. Primary amyloidoma of the brain treated with radiation therapy. Brain Path 2006; 16:S116.

77. Lachance DH, Miller RC, Lucchinetti CF, Keegan BM, Gavrilova R, Brown PD,

Weinshenker BG, Rodriguez M. Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience (Abstract RO-17). Neuro-oncol 2006 Oct; 8(4):487.

78. Porter Umphrey A, Giannini C, Kaufmann T, Lucchinetti C, Atkinson JLD, O'Neill BP. Primary central nervous system lymphoma (PCNSL) can be diagnosed with concurrent corticosteroid (CS) use: a pilot study to determine whether CS affects the diagnosis of PCNSL (Abstract TA-45). Neuro-oncol 2006 Oct; 8(4):449.

*79. Kale N, Pittock S, Lennon V, Roemer S, Lucchinetti CF. Humoral Pathology is not associated with NMO-IgG Seropositivity. (Poster) American Academy of Neurology, Boston, MA, April 2007.

*80. Magaña S, Pittock S, Lennon V, Keegan M, Weinshenker B, Lucchinetti CF. NMO-IgG Status in Fulminant CNS Inflammatory Demyelinating Disorders. (Poster) American Academy of Neurology, Boston, MA, Mult Scler. 2007 Oct; 13(Suppl 2):S9.

*81. Roemer S, Parisi J, Lennon V, Benarroch E, Lassmann H, Bruck W, Pittock S,

Weinshenker B, Wingerchuck D, Lucchinetti CF. Pattern Specific Loss of Aquaporin 4 Immunoreactivity Distinguishes Neuromyelitis Optica from Multiple Sclerosis. (Platform) American Academy of Neurology, Boston, MA, April 2007.

*82. Kelley BJ, Roemer S, Weigand S, Thomsen K, Mandrekar J, Lucchinetti CF. Cognitive and behavioral symptoms in multiple sclerosis patients with cortical demyelination. J Neuropsych Clin Neurosci 2007; 19: 231-232.

*83. Pittock SJ, Tenembaum S, Lennon VA, Ursell E, Kennedy J, Bar-Or A, Weinshenker BG, Lucchinetti CF, Banwell B. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Ann Neurol 2007; 62:S73.

84. Konig FB, Fischer I, Gunther A, Metz I, Lucchinetti CF, Bruck W. Macrophage activation patterns in active multiple sclerosis lesions. Acta Neuropathol (Berl) 2007 Sep; 114(3):316.

*85. Jacob A, Weinshenker B, Marcelo M, Wingerchuk D, Carter J, Kantarci O, Keegan M,

Shuster E, Lucchinetti C, Pittock S. Treatment of neuromyelitis optica with mycophenolate: retrospective analysis of 25 cases. (Poster) ECTRIMS, Prague, Czech Republic, October 2007. Mult Scler 2007 Oct; 13(Suppl 2):S244.

68

*86. Magaña S, Keegan M, Pittock S, Lennon V, Weinshenker B, Lucchinetti C. NMO-IgG status in fulminant CNS inflammatory demyelinating disorders and relationship with plasma exchange response in NMO spectrum disorders. (Poster) ECTRIMS, Prague, Czech Republic, October 2007. Mult Scler 2007 Oct; 13(Suppl 2):S9.

87. Matiello M, Jacob A, Pittock S, Lennon V, Lucchinetti C, Wingerchuk D, Weinshenker B. NMO-IgG predicts the outcome of recurrent optic neuritis. (Poster) ECTRIMS, Prague, Czech Republic, October 2007. Mult Scler 2007 Oct; 13(Suppl 2):S159-60.

*88. DeLuca GC, Morales Y, Roemer SF, Mandrekar J, Bruck W, Lassmann H, Kantarci O, Konig FB, Lucchinetti CF. The HLA-DRB1 locus influences phenotypic pathological outcomes in early multiple sclerosis lesions. (Poster) ECTRIMS, Prague, Czech Republic, October 2007. Mult Scler 2007 Oct; 13 (Suppl 2): S7-S273

*89. Koenig FB, Fischer I, Gunther A, Metz I, Lucchinetti CF, Bruck W. Macrophage activation patterns in active multiple sclerosis lesions. (Poster) ECTRIMS, Prague, Czech Republic, October 2007. Mult Scler 2007 Oct; 13 (Suppl 2): S140.

*90. Koenig FB, Fischer I, Gunther A, Metz I, Lucchinetti CF, Bruck W. Macrophage activation patterns in active multiple sclerosis lesions. (Poster) ECTRIMS, Prague, Czech Republic, October 2007. Acta Neuropathologica 2007; 114:316.

*91. Kale N, Konig FB, Bruck W, Lassmann H, Mandrekar JN, Thomsen K, Weigand S, Linbo L, Lucchinetti CF. Correlation of immunopathological patterns with multiple sclerosis functional composite disability in biopsy: confirmed multiple sclerosis. (Poster) ECTRIMS, Prague, Czech Republic, October 2007. Mult Scler 2007 Oct; 13(Suppl 2): S139-140.

*92. Gavrilova R, Metz I, Bruck W, Weigand S, Thomsen K, Mandrekar J, Altintas A, Erickson B, Konig F, Parisi J, Scheithauer B, Giannini C, Lassmann H, Linbo L, Lucchinetti CF. MRI correlates of immunopathological patterns. (Poster) ECTRIMS, Prague, Czech Republic, October 2007. Mult Scler 2007 Oct; 13 (Suppl 2): S273.

*93. Lucchinetti C, Metz I, Weigand S, Thomsen K, Mandrekar J, Erickson B, Bruck W, Altintas A, Konig FB, Parisi J, Scheithauer B, Giannini C, Linbo L, Lassmann H, Gavrilova R. The clinical and radiographic spectrum of biopsy-proven CNS inflammatory demyelinating disease. (Poster) ECTRIMS, Prague, Czech Republic, October 2007. Mult Scler 2007 Oct; 13 (Suppl 2): S273.

*94. Magaña S, Keegan M, Weinshenker B,Erickson BJ, Mandrekar JN, Weigand SD, Thomsen

K, Linbo L, Lucchinetti CF. Relation between MRI and therapeutic plasma exchange (PLEX) response in patients with fulminant CNS inflammatory demyelinating disorders (IDD). (Poster) American Academy of Neurology, Chicago, IL, April 2008.

*95. Jacob A, Weinshenker B, Matiello M, Wingerchuk D, Schuster E, Carter J, Keegan M,

Kantarci O, Lucchinetti C, Pittock S. Neuromyelitis optica treated with mycophenolate: Retrospective analysis of 25 cases. (Poster) American Academy of Neurology, Chicago, IL, April 2008.

*96. Young N, Roemer S, Parisi J, Weinshenker B, Lucchinetti C. Clinico-pathological correlations of perivenous versus confluent demyelination in acute inflammatory demyelinating disease. (Poster) American Academy of Neurology, Chicago, IL, April 2008.

69

*97. Roemer S, Parisi J, Bruck W, Lassmann H, Esiri M, Pittock S, Lennon V. Lucchinetti C. Neuromyelitis optica brain lesions are pathologically identical to optico-spinal lesions. (Platform) American Academy of Neurology, Chicago, IL, April 2008.

*98. Roemer S, Moll N, Ransohoff RM, Kelley B, Parisi JE, Lucchinetti CF. Cortical pathology and meningeal inflammation in early MS. (Platform) American Academy of Neurology, Chicago, IL, April 2008.

*99. McKeon A, Lennon V, Lotze T, Tenembaum S, Ness J, Rensel M, Kuntz N, Fryer JP,

Homburger H, Hunter J, Weinshenker B, Krecke K, Lucchinetti CF, Pittock S. CNS Aquaporin-4 Autoimmunity in Childhood. (Platform) American Academy of Neurology, Chicago, IL, April 2008.

*100. Roemer S, Lucchinetti CF. Cortical pathology in early MS. Consortium of MS Centers Annual Meeting, May 2008.

101. Lucchinetti, CF. Update on the MS Lesion Project. Consortium of MS Centers Annual Meeting, May 2008.

102. Erickson, BE, Lucchinetti CF. Neuroimaging of early MS. Consortium of MS Centers Annual Meeting, May 2008.

103. Keegan M, Lucchinetti CF. Plasma exchange response associated with MS pathology. Consortium of MS Centers Annual Meeting, May 2008.

*104. Abou Zeid N, Erickson BJ, Weigand S, Thomsen K, Parisi J, Linbo L, Lucchinetti CF. Apparent diffusion coefficient imaging characteristics of biopsy-proven acute inflammatory demyelinating brain lesions. ECTRIMS, Montreal, PQ, September 2008. Mult Scler 2008; 14(Suppl 1):S206. PMCID: PMC3359505

105. Konig FB, Metz I, Lucchinetti CF, Bruck W. T cell- and macrophage-associated pathology

correlates with response to corticosteroids. ECTRIMS, Montreal, PQ, September 2008. Mult Scler 2008; 14(Suppl 1):S273.

106. Linbo RA, Vandell AG, Larson NS, Keegan MB, Blaber SI, Blaber M, Sneve DM,

Lucchinetti CF, Rodriguez M, Diamandis EP, Scarisbrick IA. Association of Kallikreins with Neuron Loss and Progressive Multiple Sclerosis. Ann Neurol 2008; 64:S58.

107. *Matiello M, Magaña SM, Pittock SJ, Lennon VA, McKeon A, Kantarci O, Shuster E, Rabinstein A, Lucchinetti CF, Weinshenker BG. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. ECTRIMS, Montreal, PQ, September 2008. Mult Scler 2008; 14 (Suppl 1):S134.

108. McKeon A, Fryer JP, Apiwattanakul M, Hinson SR, Kryzer TJ, Lucchinetti CF, Weinshenker BG, Wingerchuk DM, Shuster E, Lennon VA, Pittock SJ. NMO-IgG immunofluorescence sensitivity exceeds aquaporin-4 IgG immunoprecipitation: combined assays improve sensitivity. ECTRIMS, Montreal, PQ, September 2008. Mult Scler 2008; 14 (Suppl 1):S234.

109. Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology 2008; 71:2021.

70

110. Lucchinetti C. Pathology of Progressive MS. (Platform) ECTRIMS, Dusseldorf, Germany, September 2009.

*111. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti C, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H. Interdependence of inflammation and neurodegeneration. Or: is there really neurodegeneration occurring independently from inflammation in multiple sclerosis brains? ECTRIMS, Dusseldorf, Germany, September 2009. Mult Scler 2009; 15 (Suppl S):S176. (Abstract)

*112. Hu W, Morales Y, De Luca GC, Weigand SD, Thomsen KM, Mandrekar J, Parisi JE,

Scheithauer B, Giannini C, Kantarci OH, Lucchinetti C. T-Lymphocyte Inflammation in Early Multiple Sclerosis: Evidence of Patient-Specific Set Points across Stages of Demyelinating Activity. Ann Neurol 2009; 66:S33.

113. Konig FB, Loscher A, Metz I, Muller S, Lucchinetti C, Bruck W. Astroglia pathology in early multiple sclerosis. ECTRIMS, Dusseldorf, Germany, September 2009. Mult Scler 2009; 15 (Suppl S):S273.

114. Kraskiewicz H, Ni Mhaille A, Roemer S, Lucchinetti C, Fitzgerald U. Detection of markers of endoplasmic reticulum stress in infarcted human brain and in newly-developed in vitro models of oligodendrocyte ischaemia. Glia 2009 Oct; 57(Suppl S):S59.

115. Apiwattanakul M, Matiello M, Weinshenker B, Lucchinetti C, McKeon A, Lennon V,

Carpenter A, Pittock. Intractable vomiting as the initial presentation of autoimmune aquaporin-4 water channelopathy. American Academy of Neurology, Toronto, ON, April 2010. Neurology 2010; 74(Suppl 2):A164-5. (Abstract)

*116. Bunyan RF, Kelley BJ, Ransohoff RM, Thomsen K, Scheithauer BW, Parisi J, Giannini C,

Linbo LK, Roemer S, Lucchinetti CF. Spectrum of clinical symptoms in early MS with pathologically confirmed cortical demyelination. American Academy of Neurology, Toronto, ON, April 2010. Neurology 2010; 74(Suppl 2):A365.

117. Lucchinetti CF, Frischer JM, Parisi JE, Weigand SD, Thomsen KM, Brueck W, Lassmann H, Mandrekar J. MS immunoglobulin heterogeneity persists in active lesions throughout duration of disease: Relation to plaque type and clinical course. American Academy of Neurology, Toronto, ON, April 2010. Neurology 2010; 74(Suppl 2):A391.

*118. Magaña S, Weigand S, Thomsen K, Mandrekar J, Lucchinetti C, Keegan M. Duration

following severe attacks of CNS demyelinating disease to plasma exchange initiation: How long is too long? American Academy of Neurology, Toronto, ON, April 2010. Neurology 2010; 74(Suppl 2):A370.

*119. Popescu BF, Parisi JE, Cabrera-Gómez JA, Pittock SJ, Lennon VA, Weinshenker BW,

Lucchinetti CF. Neuropathologic features of the area postrema and the floor of the fourth ventricle in neuromyelitis optica. American Association of Neuro-pathologists, June 2010, Philadelphia, PA. JNEN 2010; 69:535.

*120. Popescu BF, Ransohoff RM, Moll NM, Parisi JE, Scheithauer BW, Weigand SD,

Mandrekar J, Roemer SF, Lucchinetti CF. Meningeal infiltrates are present in early MS

and may contribute to early cortical demyelination. 39th Annual Meeting of the Child Neurology Society, October 2010, Providence, RI. Ann Neurol 2010; 68:S54.

71

*121. Costanzi C, Bourdette D, Parisi J, Woltjer R, Rodriguez F, Steensma D, Lucchinetti CF. Plasma Cell Neoplasm with Crystal-storing Histiocytosis Mimicking Multiple Sclerosis. American Neurological Association, September 2010, San Francisco, CA. Ann Neurol 2010; 68:S58.

122. Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sorensen PS, Laursen H. Demyelination versus remyelination in progressive multiple sclerosis. 17th International Congress of Neuropathology, September 2010, Salzburg, Austria. Brain Path 2010; 20:84.

*123. Costanzi C, Thomsen KM, Linbo L, Lucchinetti CF. CNS Inflammatory Demyelinating

Disease in the Elderly: Clinical Spectrum of Pathologically Confirmed Disease. Italian Neurological Association, October 2010, Catania, Italy.

*124. Bunyan RF, Popescu BF, Parisi JE, Ransohoff RM, Lucchinetti CF. A case of multiple

sclerosis presenting with inflammatory cortical demyelination. (Poster) American Academy of Neurology, Honolulu, HI, April 2011. Neurology 2011; 76 (Suppl 4): A64-65.

*125. Bunyan RF, Popescu BF, Parisi JE, Scheithauer BW, Giannini C, Lucchinetti CF. Cortical demyelination is frequent in early childhood CNS inflammatory demyelinating disease. (Poster) American Academy of Neurology, Honolulu, HI, April 2011. Neurology 2011; 76 (Suppl 4):A359-60.

*126. Costanzi C, Matiello M, Lucchinetti C, Weinshenker B, Mandrekar J, Prabin T, Pittock S, McKeon A. Azathioprine in NMO: Tolerability, efficacy, and predictors of benefit. (Poster) American Academy of Neurology, Honolulu, HI, April 2011. Neurology 2011; 76 (Suppl 4):A534.

*127. Costanzi C, Bunyan R, Guo Y, Parisi J, Linbo L, Lucchinetti CF. Clinical-radiological- pathological spectrum of CNS inflammatory demyelinating disease in the elderly. (Poster) American Academy of Neurology, New Orleans, LA, April 2012. Neurology 2012; 78:P03.048.

128. Quek A, McKeon A, Lennon V, Mandrekar J, Iorio R, Jiao Y, Costanzi C, Weinshenker B, Wingerchuk D, Lucchinetti C, Shuster E, Pittock S. Effects of age and sex on aquaporin-4 autoimmunity. (Poster) American Academy of Neurology, New Orleans, LA, April 2012. Neurology 2012; 78:S60.002.

129. Iorio R, Lucchinetti C, Lennon V, Costanzi C, Hinson S, Weinshenker B, Pittock S. Syndrome of Inappropriate Antidiuresis May Herald or Accompany Neuromyelitis Optica. American Academy of Neurology, New Orleans, LA, April 2012. Neurology 2012; 78:P07.064. (Poster).

130. Rahmlow M, Sorenson E, Crum B, Lucchinetti C, Kantarci O, Carter J. The co-occurrence of MS and ALS: Chance or shared biology? (Poster) American Academy of Neurology, New Orleans, LA, April 2012. Neurology 2012; 78:P02.147.

*131. Guo Y, Goldman J, Lennon VL, Parisi JE, Lucchinetti CF. Rosenthal fibers in

neuromyelitis optica. (Platform) American Academy of Neuropathology, Chicago, IL, June, 2012; JNEN 2012; 71:552.

72

*132. Jenthoft M, Guo Y, Lennon VL, Parisi JE, Lucchinetti CF. Aquaporin-4

immunohistochemistry aids pathological diagnosis of neuromyelitis optica spectrum disorder. (Platform) American Academy of Neuropathology, Chicago, IL, June 2012.

133. Pfeifenbring S, Bunyan RF, Metz I, Lucchinetti CF, Brück W. Axonal Damage in

Inflammatory Demyelinating Lesions of Paediatric Patients. ECTRIMS, Lyon, France, October 2012.

134. Pittock SJ, McKeon A, Mandrekar JN, Weinshenker BG, Lucchinetti CF, Wingerchuk DM. T1826. Pilot Clinical Trial of Eculizumab in AQP4-IgG-Positive NMO. American Neurological Association, Boston, MA, October 2012; Ann Neurol 72: S116.

135. Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek MLA, Smith CY, McKeon A, Costanzi C,

Iorio R, Weinshenker BG, Wingerchuk DM, Shuster EA, Lucchinetti CF, Pittock SJ. What Is the Frequency of [ldquo]Truly[rdquo] AQP4-IgG-Negative NMO and Does It Differ Phenotypically from Seropositive Disease? American Academy of Neurology, San Diego, CA, March 2013.

136. Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek MLA, Smith CY, McKeon A, Costanzi C, Iorio R, Weinshenker BG, Wingerchuk DM, Shuster EA, Lucchinetti CF, Pittock SJ. A Systematic Clinico-Serologic Study of Recurrent Longitudinally Extensive Transverse Myelitis (rTM) and Comparison with NMO. American Academy of Neurology, San Diego, CA, March 2013.

*137. Guo Y, Grouse CK, Milone M, Lassmann H, Lennon VA, Pittock SJ, Stefoski D, Topel J,

Balabanov R, Lucchinetti CF. HyperCKemia and Skeletal Muscle Pathology in Neuromyelitis Optica. (Late-breaking news.) American Neurological Association, New Orleans, LA, October 2013. J Neuropathol Exp Neurol. 2013 Jun; 72(6):550.

138. Metz I, Weigand S, Popescu B, Stadelmann C, Frischer J, Parisi J, Guo Y, Lassmann H, Brück W, Lucchinetti C. Immunopathologic heterogeneity persists in early active multiple sclerosis lesions. (Platform) 29th ECTRIMS Congress and 18th Annual Congress of Rehabilitation in MS (RIMS), Copenhagen, Denmark, October 2013.

*139. Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, Lucchinetti CF, Pittock SJ, Tippmann-Peikert M, Wirrell EC, McKeon A. DPPX Autoantibody: Frequency, Clinical Accompaniments and Outcomes. (Platform) American Academy of Neurology, Philadelphia, PA, April-May 2014.

140. Clardy SL, Lucchinetti CF, Krecke KN, Lennon VA, O’Toole O, Weinshenker BG, Boyd CD, Krieger S, McGraw C, Yong G, Pittock SJ. Hydrocephalus in Neuromyelitis Optica. (Poster) American Academy of Neurology, Philadelphia, PA, April-May 2014.

*141. Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, Appendino JP, Lucchinetti CF, Matsumoto JY, Pittock SJ, Sandroni P, Tippmann-Peikert M, Wirrell EC, McKeon A. DPPX potassium channel antibody: Frequency, clinical accompaniments, and outcomes in 20 patients. Neurology Update Meeting, Dublin, Ireland, October, 2014.

142. Fryer JP et al. Neuromyelitis Optica and Autoimmune Encephalitis. (Platform) American Academy of Neurology, Philadelphia, PA, April-May 2014.

73

*143. Tobin WO, Popescu BF, Lowe V, Pirko I, Kantarci K, Fields JA, Boeve BF, Lucchinetti CF. Multiple Sclerosis masquerading as Alzheimer type dementia – Clinical, radiological and pathological findings. Alzheimer’s Association International Conference, Copenhagen, Denmark, July 2014 (Poster).

*144. Caulfield M, Kaptzan T, LaFrance-Corey R, Guo Y, Howe C, Lucchinetti C. Astrocytes orchestrate early granulocyte responses in neuromyelitis optica. (Platform – Nanosymposium) Society for Neuroscience, Washington DC, November 2014.

145. Wingerchuk D, Weinshenker B, Carter J, Pittock S, Lennon VA, McKeon A, Lucchinetti C,

Keegan M. Prospective evaluation of maintenance plasma exchange (mplex) for attack prevention in neuromyelitis optica spectrum disorder: preliminary feasibility, safety, and efficacy data. American Academy of Neurology 67th Annual Meeting, April 18-25, 2015, Washington, DC. (poster).

146. Flanagan EP, Weinshenker BG, Krecke KN, Lennon VA, Lucchinetti CF, McKeon A, Wingerchuk DM, Shuster EA, Jiao Y, Horta ES, MD; Pittock SJ. Short myelitis lesions in aquaporin-4-igg-positive neuromyelitis optica spectrum disorders. American Academy of Neurology 67th Annual Meeting, April 18-25, 2015, Washington, DC. (Platform - Neuromyelitis Optica).

*147. Tillema J-M, Weigand S, Port J, Mandrekar J, Shu Y, Lucchinetti CL, Pirko I. MRI

Reveals Connectivity of Cortical Lesions to White Matter Lesions in Multiple Sclerosis. American Academy of Neurology 67th Annual Meeting, April 18-25, 2015, Washington, DC. ( Poster)

*148. Tobin WT, Lucchinetti CL, et. al. Case Vignettes Presentation. Multiple Sclerosis and

Neuromyelitis Optica. February, 2015. Phoenix, Arizona (presentation).

*149. Lucchinetti CF, Guo Y. Involvement of Cerebrospinal Fluid-Brain Barriers in Neuromyelitis Optica: Pathogenic Implications. American Neurological Association’s (ANA) 2015 Annual Meeting. September 27–29, 2015, Chicago Marriott Downtown, 540 N Michigan Avenue, Chicago, IL.

150. Flanagan E, Cabre P, Weinshenker B, St. Sauver J, Majed M, Lennon V, Lucchinetti CL, McKeon A, Wingerchuk D, Mandrekar J, Jacobson DJ, Sagen S, Schmeling JE, Fryer J, Matiello M, Kale N, Borders-Robinson A, Pittock S. Ring-Enhancing Spinal Cord Lesions in Neuromyelitis Optica Spectrum Disorder Abstract 2086, (Poster 145, Poster Session P4). American Academy of Neurology 68th Annual Meeting in Vancouver, BC, Canada, April 15- 21, 2016.

151. Majed M, Lucchinetti CL, Benarroch E, Sagen JA, Pittock SJ. Autoimmune AQP4 Channelopathy and Bradycardia: Expanding the NMOSD Spectrum (Abstract 3233, Poster 306, Poster Session P5). American Academy of Neurology 68th Annual Meeting in Vancouver, BC, Canada, April 15-21, 2016.

152. Keegan M, Guo Y, Okuda D, Siva A, Pelletier D, Kantarci O, Lucchinetti CL, Lebrun Frenay C. Radiologically Isolated Syndrome: Pathologically Defined as Demyelinating Disease (Abstract 3631, Poster 391, Poster Session P1), American Academy of Neurology 68th Annual Meeting in Vancouver, BC, Canada, April 15-21, 2016.

74

153. Tobin W, Guo Y, Krecke K, Parisi J, Lucchinetti C, Pittock S, Mandrekar J, Dubey D, Debruyne J, Keegan BM. Clinical, Radiographic and Pathological Features of CLIPPERS (Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids). (Abstract 1862, Poster 109, Poster Session P6). American Academy of Neurology 68th Annual Meeting in Vancouver, BC, Canada, April 15-21, 2016. PMID29050399.

154. Flanagan E, Cabre P, Weinshenker B,St. Sauver J, Majed M, Lennon V, Lucchinetti CL,

McKeon A, Wingerchuk D, Mandrekar J, Jacobson DJ, Sagen J, Schmeling JE, Fryer J, Matiello M, Kale N, Borders-Robinson A, Pittock S. Epidemiology of Aquaporin-4 Autoimmunity and Neuromyelitis Optica Spectrum: A Comparison of Two Ethnically Divergent Populations. (Abstract 2510). American Academy of Neurology 68th Annual Meeting in Vancouver, BC, Canada, April 15-21, 2016.

155. Sethi VV, Nair G, Ha SK, Popescu B, Schindler MK, Smith BR, Absinta M, Sati P, Wüthrich C, Webb SM, Kumar S, Ohayon J, Lucchinetti CL, Koralnik I, Major E, Nath A, Cortese I, Reich DS. Evolving dark band on T2*-weighted images is characteristic of PML and indicates iron deposition - a combined MRI, XRF & histopathology study. 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis which will take place in London, 14 - 17 September 2016 (oral presentation).

156. Majed M, Benarroch E, Lucchinetti CL, Krecke K, Sagen J, Guo Y, Costanzi C, Pittock S. Central Dysregulation of Heart Rate and Blood Pressure in Autoimmune AQP4 Channelopathy: Expanding the neuromyelitis optica spectrum disorder (NMOSD). American Academy of Neurology 69th Annual Meeting, April 22 - 28, 2017. Boston, MA. (oral presentation).

157. Sagen J, Majed M, Lennon B, Lucchinetti CL, Fryer J, Pittock S. Placental transmission of AQP4-IgG to neonate from mothers with neuromyelitis optica spectrum disorder (NMOSD). American Academy of Neurology 69th Annual Meeting, April 22 - 28, 2017 in Boston, MA. (oral presentation).

158. Kabiraj P, Caulfield M, McCarthy C, Johnson R, Lucchinetti CL, Howe H. The extracellular glutamate-to-glutamine ratio modulates glycolysis in primary murine astrocytes. Neuroscience 2017, November 11-15, Washington DC.

159. Mayo Clinic Glial Autoimmunity Study: Glial autoantibody (AQP4/MOG/GFAP) serostatus in recurrent longitudinally extensive transverse myelitis" has been accepted for a poster presentation at the American Academy of Neurology 70th Annual Meeting, April 21 to April 27, 2018 in Los Angeles, CA.

160. Lopez-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, Jitprapaikulsan J, Kothapalli N, Tillema JM, Chen J, Weinshenker B, Wingerchuk D, Sagen J, Gadoth A, Lennon VA, Keegan BM, Lucchinetti C, Pittock SJ . Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. Platform presentation, American Academy of Neurology 70th Annual Meeting, April 23, 2018, Los Angeles, CA.

161. The Mayo Clinic Glial Autoimmunity study: Persistence of MOG-IgG seropositivity predicts relapse after ADEM in both children and adults" has been accepted for a platform presentation at the American Academy of Neurology 70th Annual Meeting, April 21 to April 27, 2018 in Los Angeles, CA.
















75

162. Neuronal Intermediate Filament Autoimmunity" has been accepted for a platform presentation at the American Academy of Neurology 70th Annual Meeting, April 21 to April 27, 2018 in Los Angeles, CA

163. Temporal Evolution of DWI and Gadolinium Enhancement in Balo's Variant of Multiple Sclerosis suggests a Cytotoxic Oligodendrocytopathy preceding Blood Brain Barrier Breakdown in Acute Demyelination. ASNR 57th Annual Meeting, May 18-23, 2019 in Boston, MA.

164. Kalinowska-Lyszczarz A, Tobin WO, Tillema J-M, Guo Y, Weigand SD, Giraldo-Chica M, Port JD, Lucchinetti CF. Long-term clinical, neuroimaging and cognitive outcomes in three immunopathologically classified patterns of Multiple Sclerosis. ECTRIMS 2019 which will be held together with the 24th Annual Conference of RIMS from 11-13 September in Stockholm, Sweden. (poster)

165. Kalinowska-Lyszczarz A, Tobin WO, Tillema J-M, Guo Y, Weigand SD, Giraldo-Chica M, Port JD, Lucchinetti CF. Long-term follow-up on clinical, radiographic and cognitive outcomes in pathologically confirmed CNS inflammatory demyelinating disease. ECTRIMS 2019 which will be held together with the 24th Annual Conference of RIMS from 11-13 September 2019 in Stockholm, Sweden. (oral presentation).

166. P. Kabiraj, C. McCarthy, O. Gakh, R. Johnson, C. Lucchinetti, C. L. Howe “Morphology influence the astrocytic bioenergetic preferences but not the chemokine release in vitro”. Society for Neuroscience 2019 in Chicago, IL.

167. C. Vasquez, P. Kabiraj, C. McCarthy, C. Howe, C. Lucchinetti. “Differential metabolic regulation of astrocyte chemokine release”. Neuroimmune Communication in Health and Disease Conference, Gordon research conference, 2019, San Diego, CA.

168. P. Kabiraj, M. Caulfield, C. McCarthy, R. Johnson, C. Lucchinetti, C. Howe. “The extracellular glutamate-to-glutamine ratio modulates glycolysis in primary murine astrocytes”. Society for Neuroscience 2017, Washington DC.

Updated: February 26, 2020

1 CURRICULUM VITAE PERSONAL INFORMATION › files › 2020 › Lucchinetti CV.pdf · Clinical &...

Documents

Transcript of 1 CURRICULUM VITAE PERSONAL INFORMATION › files › 2020 › Lucchinetti CV.pdf · Clinical &...